**ERS Task Force guideline for the diagnosis of primary ciliary dyskinesia**

Lucas JS1,2, Barbato A3, Collins SA1,2, Goutaki M4,5, Behan L1,2, Caudri D6,7, Dell S8, Eber E9, Escudier E10,11, Hirst RA12, Hogg C13, Jorissen M14, Latzin P5, Legendre M10,11, Leigh MW16, Midulla F17, Nielsen KG18, Omran H19, Papon JF20,21, Pohunek P22, Redfern B23, Rigau D24, Rindlisbacher B25, Santamaria F26, Shoemark A13, Snijders D3, Tonia T4, Titieni A19, Walker WT1,2, Werner C19, Bush A13, Kuehni CE4

Corresponding Author; Jane S Lucas. Primary Ciliary Dyskinesia Centre, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD. UK. jlucas1@soton.ac.uk

Keywords; primary ciliary dyskinesia, diagnosis, nitric oxide, ciliary function, genetics, immunofluorescence

1. Primary Ciliary Dyskinesia Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
2. University of Southampton Faculty of Medicine, Academic Unit of Clinical and Experimental Medicine, Southampton, UK
3. Primary Ciliary Dyskinesia Centre, Department of Woman and Child Health (SDB), University of Padova, Italy
4. Institute of Social and Preventive Medicine, University of Bern, Switzerland
5. Department of Paediatrics, Inselspital, University Hospital of Bern, University of Bern, Switzerland
6. Telethon Kids Institute, The University of Western Australia, Subiaco, Australia
7. Dept. of Pediatrics/ Respiratory Medicine, Erasmus University, Rotterdam, The Netherlands
8. Division of Respiratory Medicine, The Hospital for Sick Children, Departments of Pediatrics and Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
9. Division of Paediatric Pulmonology and Allergology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
10. Service de Génétique et Embryologie Médicales, Centre de Référence des Maladies Respiratoires Rares, Hôpital Armand Trousseau, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
11. Inserm UMR\_S933, Sorbonne Universités (UPMC Univ Paris 06), Paris, France
12. Centre for PCD Diagnosis and Research,Department of Infection, Immunity and Inflammation, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester, UK
13. Departments of Paediatrics and Paediatric Respiratory Medicine, Imperial College and Royal Brompton Hospital, London UK
14. Experimental Otorhinolaryngology Research Group, Department of Neurosciences, KULeuven, Leuven, Belgium.
15. ENT Department, University Hospitals Leuven, Leuven, Belgium
16. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
17. Paediatric Department, Sapienza University of Rome, Italy
18. Danish PCD & chILD Centre, CF Centre Copenhagen, Paediatric Pulmonary Service, Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Denmark
19. Department of Pediatrics, University Hospital Muenster, Muenster Germany
20. AP-HP, Hôpital Kremlin-Bicetre, service d’ORL et de chirurgie cervico-faciale, Le Kremlin-Bicetre, 94275, France;
21. Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, F-94270, France
22. Paediatric Department, Second Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, 150 06 Prague 5, Czech Republic
23. Patient Representative, PCD Family Support Group, Registered Charity No. 104 9931 Ref: PCD150624FC01 , UK
24. Iberoamerican Cochrane Center, Barcelona, Spain
25. German speaking European Patient Association based in Germany “Kartagener Syndrom und Primäre Ciliäre Dyskinesie e. V.”
26. Pediatric Pulmonology, Department of Translational Medical Sciences, Federico II University, Azienda Ospedaliera Universitaria Federico II, Naples, Italy

**Take Home Message:** International ERS guidelines recommend a combination of tests to diagnose PCD

**Acknowledgements**

Members of the Task Force are also participants in BEAT-PCD (COST Action BM 1407). Lucas, Nielsen, Kuehni, Hogg , Leigh, and Omran received funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement n8305404 (BESTCILIA). Lucas, Behan, Walker and Collins were supported by NIHR Respiratory Biomedical Research Unit (BRU) at University Hospital Southampton NHS Foundation Trust and AAIR Charity. Bush is an NIHR Senior Investigator, and was supported by the NIHR Respiratory Disease BRU at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. Goutaki was supported by the following national grants: Bernese Lung League, Milena- Pro Kartagener foundation and Swiss National Foundation 32003B\_162820/1. Dell and Leigh received funding from the National Institutes of Health (NIH) (U54HL096458)through the Genetic Disorders of Mucociliary Clearance Consortium (GDMCC), an initiative of the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), and the National Heart, Lung & Blood Institute (NHLBI);

Abstract

The diagnosis of primary ciliary dyskinesia is often confirmed with standard, albeit complex and expensive tests. In many cases, however, the diagnosis remains difficult despite the array of sophisticated diagnostic tests. There is no ‘gold standard’ reference test. Hence, a task force supported by the European Respiratory Society has developed this guideline to provide evidence-based recommendations on diagnostic testing, especially in the light of new developments in such tests, and the need for robust diagnoses of patients who might enter randomised controlled trials of treatments. The guideline is based on pre-defined questions relevant for clinical care, a systematic review of the literature, and assessment of the evidence using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. It focuses on: clinical presentation, nasal nitric oxide, analysis of ciliary beat frequency and pattern by high-speed video-microscopy analysis, transmission electron microscopy, genotyping and immunofluorescence. It then used a modified Delphi survey to develop an algorithm for the use of diagnostic tests to definitively confirm and exclude the diagnosis of PCD; also to provide advice when the diagnosis is not conclusive. Finally, this guideline proposes a set of quality criteria for future research on the validity of diagnostic methods for PCD.

Introduction

PCD represents a clinical and genetic heterogeneous group of respiratory ciliopathies, with reduced muco-ciliary clearance of the airways. The various mutations result in different clinical and pathological patterns, contributing to the challenges of diagnosis. There is no single gold standard diagnostic test for primary ciliary dyskinesia (PCD) [1]; current diagnosis requires a combination of technically demanding investigations, including nasal nitric oxide (nNO), high-speed video microscopy analysis (HSVA) and transmission electron microscopy (TEM). Historically clinicians used the saccharine test to screen for PCD, but this is no longer advocated [2]. Furthermore, more sophisticated diagnostic tests that might improve diagnostic accuracy (genotyping, immunofluorescence (IF) of ciliary proteins and EM tomography) are becoming increasingly available.

The availability of tests varies across Europe [3]; this has partially improved recently in response to collaborations including a former Task Force(2006-9) of the European Respiratory Society (ERS) [2–4] and FP-7 funded BESTCILIA. The ERS Task Force published a consensus statement in 2009 [2] to guide diagnostic testing and BESTCILIA has recently introduced diagnostic testing into three countries where services did not previously exist. Since the 2009 statement, a number of groups and consortia have investigated the accuracy of various diagnostic tests for PCD, providing the opportunity to advance the state of diagnostics by developing evidence based guidelines. Therefore, in 2014 a new PCD ERS Task Force consisting of adult and paediatric physicians from pulmonology and ENT disciplines along with diagnostic scientists was established; it aimed to develop evidence based guidelines for the diagnosis of PCD. This is important for the appropriate clinical management and prognosis of individual patients with suspected or eventually confirmed PCD; to ensure patients with PCD are correctly diagnosed whilst avoiding the problems of false positive diagnoses. It should also ensure a definitive diagnosis before PCD patients are enrolled in randomised controlled clinical trials of treatment.

Methods

The methods are described in detail in the supplementary file.

Task Force Composition

In brief, the panel consisted of a multidisciplinary group of clinicians and scientists with recognised expertise in the diagnosis of primary ciliary dyskinesia; junior members/ trainees affiliated to European PCD centres were active members of the committee (Supplementary Table 1). Methodologists from the ERS provided expertise in guideline development following the GRADE approach for diagnostic tests [5]. Panel members disclosed potential conflicts of interest according to ERS policies at the start of the Task Force and prior to publication of this manuscript.

Patient-Important Outcomes

The GRADE approach emphasizes the importance of recommendations based on the impact on patient-important outcomes [6]. The patient representatives to the Task Force fully endorsed that an accurate diagnosis was an important outcome, because it leads to a better recognition of their problems by physicians and more effective treatment, and thus improves their health and quality of life. This was confirmed by our questionnaire survey of 352 PCD patients from 25 countries, and 20 in-depth interviews [7]. However, diagnostic accuracy studies do not provide direct evidence for the improvement of patient-important outcomes; consequently, the confidence in results of test accuracy studies was judged at best as moderate.

Formulation of the Topics and Questions

The Task Force members agreed that six facets of PCD diagnostics should be evaluated: clinical symptoms, nNO, HSV, TEM, genotype and IF labelling of ciliary proteins. We evaluated each test to see whether it should be included in the diagnostic pathway for PCD, using a ‘PICO’ structured question: “**P**atients suspected of having PCD, **I**nvestigated by [nNO, TEM etc], when **C**omparing patients with a final positive or negative diagnostic outcome, what was the diagnostic accuracy (**O**utcome) of the test?” The PICO questions for each test were finalised during several rounds of teleconferences and email discussions (Supplementary Table 2).

The essential inclusion criterion for studies was that they must have included consecutive patients referred for PCD testing, in whom the PCD diagnosis was then either confirmed or excluded; we excluded studies if patients had already had previous diagnostic testing. In the absence of such studies, in the narrative review we discussed case control studies which compared PCD patients with healthy controls, or with patients suffering from other respiratory diseases (e.g. CF). . Results from such studies cannot be generalised to the clinical situation, where patients with PCD must be distinguished from patients referred for similar complaints, but without PCD. Thus, the results from case control studies are far less relevant for clinical care. The main limitation for this project was the lack of a gold standard diagnostic test for PCD. In the absence of this, we compared the diagnostic performance indicators (e.g. sensitivity and specificity) to the authors’ final decision regarding positive/negative PCD diagnosis based on all available tests.

The Task Force also agreed on a list of less structured questions relevant to PCD diagnostics for the narrative discussion. As the evidence for these questions were not formally graded, they were not used for recommendations.

Literature Search Methods

We searched Medline and Embase databases (accessed through Ovid) from 1st January 1996 to 14th March 2016. Full details are provided in the supplementary file. In brief, titles and abstracts were screened; the full text was then reviewed for papers which potentially fulfilled criteria for inclusion. These manuscripts were checked for completeness by the Task Force panel to ensure all data fulfilling the *a priori* inclusion criteria were present. PRISMA flow diagrams show the search process for each WG (supplementary file figure 1).

Quality of Evidence and Strength of Recommendations

We used the GRADE approach through the entire process, from grading the quality of evidence, to deciding on the strength of the recommendations [8, 9]. Full details are provided in the supplementary file including reasons for downgrading the confidence in the evidence (summary of evidence tables)Recommendations were made based on the strength of evidence and other factors such as overall accuracy of the test (sensitivity and specificity), confidence in the net accuracy (range of sensitivity/sensitivity from included studies and/or confidence intervals of net sensitivity and specificity) and considerations such as patient acceptability of the test, feasibility of testing and how accessible the test is. The four tests where evidence based recommendations were made, were all acceptable to the patient, feasible and acceptable.” Consensus statement for confirming or excluding PCD

We used a modified Delphi survey to reach a consensus regarding the use of diagnostic tests to definitively confirm and exclude the diagnosis of PCD; also to provide advice regarding patients who do not have a definitive diagnosis but diagnostic tests suggest that the diagnosis is highly likely or inconclusive. The methods are detailed in the on-line supplementary file.

Results

The results of the evidence assessment gave rise to the recommendations in Table 1.

|  |
| --- |
| Recommendations |
| Which patients should be referred for diagnostic testing?  Based on MODERATE confidence in the evidence:   1. We recommend that patients are tested for PCD if they have severali of the following features: persistent wet cough; situs anomalies; congenital cardiac defects; persistent rhinitis; chronic middle ear disease with or without hearing loss; a history in term infants of neonatal upper and lower respiratory symptoms or neonatal intensive care admittance (strong recommendation). 2. Patients with normal situs presenting with symptoms suggestive of PCD (as listed in recommendation 1) should be referred for diagnostic testing (strong recommendation). 3. Siblings of patients should be tested for PCD, particularly if they have symptoms suggestive of PCD (as listed in recommendation 1) (strong recommendation). 4. We suggest the use of combinations of distinct PCD symptoms and predictive tools (e.g. PICADAR) to identify patients for diagnostic testing (weak recommendation). |
| In patients suspected of having PCD, should nasal nitric oxide be used as a diagnostic tool?  Based on MODERATE confidence in the evidence, we recommend that:   1. Nasal nitric oxide measurement should be used as part of the diagnostic work-up of schoolchildren over 6 years and adults suspected of having PCD, preferably using a chemiluminescence analyser with a velum closure technique (strong recommendation). 2. In children under 6 years suspected of having PCD, we suggest nasal nitric oxide measurement using tidal breathing as part of the diagnostic work-up (weak recommendation).   Remark - we suggest that patients presenting with a strong clinical history should undergo further testing, even if nNO is normal (weak recommendation). |
| In patients suspected of having PCD, should HSVA be used as a diagnostic tool?  Based on LOW confidence in the evidence, we recommend:   1. High speed video analysis, including ciliary beat frequency and beat pattern analysis, should be used as part of the diagnostic work-up of patients suspected of having PCD (weak recommendation). 2. Ciliary beat frequency should not be used without assessment of ciliary beat pattern in diagnosing PCD (strong recommendation). 3. To improve diagnostic accuracy of HSVA, CBF/P assessment should be repeated after ALI culture (strong recommendation). |
| In patients suspected of having PCD, should TEM be used as a diagnostic tool? Based on LOW confidence in the evidence, we recommend:   1. Ciliary ultrastructure analysis by transmission electron microscopy should be used as part of the diagnostic work-up of patients suspected of having PCD (strong recommendation). 2. Further diagnostic investigations should be performed in patients with normal ultrastructure if the clinical history is strong (strong recommendation).2 3. In patients with hallmark ciliary ultrastructure defects for PCD further confirmatory diagnostic investigations are not required3. (strong recommendation). |
| In patients suspected of having PCD, should genotyping be used as a diagnostic tool?  There were no studies that fulfilled inclusion criteria to answer this question.  Statements to assist the clinician are made in the genetics sections but these are NOT evidence based. |
| In patients suspected of having PCD, should IF be used as a diagnostic tool?  There were no studies that fulfilled inclusion criteria to answer this question.  Statements to assist the clinician are made in the IF sections but these are NOT evidence based. |

Table 1. Evidence-based recommendations for the use of each of the six tests considered for PCD diagnosis. Available evidence does not allow to be more specific; minimum number depends on the type of symptoms; 2normal ciliary ultrastructure, as resolvable by transmission electron microscopy, does not exclude the diagnosis of PCD (16% PCD positive patients have TEM without a detectable defect); 3patients with hallmark ciliary ultrastructure defects for PCD (absence of outer dynein arms, combined absence of inner and outer dynein arms, inner dynein arm absence combined with microtubular disarrangement), assessed by TEM, almost always have PCD (false positive results are very rare ≈0.7%)

Clinical features

Summary of recommendations

Which patients should be referred for diagnostic testing?

Based on MODERATE confidence in the evidence:

1. We recommend that patients are tested for PCD if they have several1 of the following features: persistent wet cough; situs anomalies; congenital cardiac defects; persistent rhinitis; chronic middle ear disease with or without hearing loss; a history in term infants of neonatal upper and lower respiratory symptoms or neonatal intensive care admittance (strong recommendation).
2. Patients with normal situs presenting with symptoms suggestive of PCD (as listed in recommendation 1) should be referred for diagnostic testing (strong recommendation).
3. Siblings of patients should be tested for PCD, particularly if they have symptoms suggestive of PCD (as listed in recommendation 1) (strong recommendation).

Footnote: Available evidence does not allow to be more specific; minimum number depends on the type of symptoms.

*Review of evidence directly addressing the question “in patients suspected of having PCD, which clinical features predict a positive diagnosis”?*

Our search identified 1269 studies of which two directly answered the question and were included in the quantitative synthesis (Supplementary Figure 1) and an additional 6 contributed to the narrative review. We excluded 1217 publications based on titles and abstracts. After full text review we excluded 44 of the remaining 52 studies because they did not fulfil the inclusion criteria (Supplementary table 3).

Two studies, Behan *et al* [10] and Shapiro *et al*[11], were suitable to provide evidence for our recommendations. They included 1408 patients (Table 2).

|  |  |  |
| --- | --- | --- |
| **Clinical Manifestation** | **Sensitivity (95% C.I.)** | **Specificity (95% C.I.)** |
| **Neonatal manifestations** | | |
| Neonatal chest symptoms | 0.75 (0.63-0.84) | 0.83 (0.79-0.84) |
| Neonatal rhinitis | 0.27 (0.17-0.38) | 0.94 (0.91-0.95) |
| Neonatal respiratory support | 0.41 (0.30-0.53) | 0.93 (0.90-0.95) |
| Neonatal unit admission | 0.61 (0.49-0.72) | 0.86 (0.83-0.89) |
| **Upper respiratory manifestations after the postnatal period** | | |
| Chronic rhinitis | 0.81 (0.70-0.89) | 0.43 (0.38-0.47) |
| Chronic serous otitis media | 0.57 (0.45-0.69) | 0.81(0.77-0.84) |
| Chronic acute otitis media | 0.33 (0.23-0.45) | 0.75 (0.71-0.79) |
| Hearing loss | 0.49 (0.38-0.61) | 0.84 (0.81-0.87) |
| Chronic ear perforation | 0.12 (0.06-0.22) | 0.91 (0.88-0.93) |
| Ear surgery | 0.32 (0.22-0.44) | 0.86 (0.82-0.88) |
| Chronic sinusitis | 0.28 (0.19-0.40) | 0.76 (0.72-0.79) |
| **Lower respiratory manifestations after the postnatal period** | | |
| Chronic wet cough | 0.93 (0.84-0.98) | 0.15 (0.12-0.18) |
| Recurrent wheeze | 0.48 (0.36-0.60) | 0.62 (0.57-0.65) |
| Previous pneumonia | 0.41 (0.30-0.53) | 0.65 (0.61-0.69) |
| Bronchiectasis | 0.29 (0.20-0.41) | 0.68 (0.64-0.72) |
| **Other manifestations (various ages)** | | |
| Situs anomalies\*\* | 0.51 (0.46-0.56) | 0.94 (0.92-0.95) |
| Congenital heart disease | 0.08 (0.03-0.17) | 0.98 (0.97-0.99) |
| Developmental delay | 0.11 (0.05-0.20) | 0.94 (0.91-0.96) |
| Hydrocephalus | 0.01 (0.00-0.08) | 0.99 (0.98-1.00) |
| Subfertility\* | 0.91 (0.57-1.00) | 0.82 (0.74-0.87) |
| **Family history (any age)** | | |
| Of PCD in siblings | 0.24 (0.15-0.35) | 0.98 (0.97-0.99) |
| Of PCD in extended family | 0.05 (0.02-0.14) | 0.99 (0.97-1.00) |
| Of asthma | 0.16 (0.09-0.27) | 0.66 (0.62-0.70) |
| Of bronchiectasis | 0.04 (0.01-0.12) | 0.96 (0.93-0.97) |
| Of otitis media | 0.07 (0.02-0.16) | 0.89 (0.86-0.92) |
| **Clinical scores** | | |
| PICADAR (score>5) | 0.90 (0.81-0.96) | 0.75 (0.70- 0.80) |

Table 2. Summary of reported clinical manifestations in studies included in the quantitative analysis. All data from Behan *et al* (641 eligible referrals, 75 (12%) had PCD)[10] but data on subfertility\* are from a subgroup of 152 referrals where 11 (7%) had PCD). Data on situs anomalies\*\* are from Behan *et al* and Shapiro *et al* (767 referrals) [11].

Behan *et al* analysed data from 868 consecutive paediatric and adult patients [10]. Those with inconclusive or incomplete results (227) were excluded, leaving 641 for analysis. All patient data were collected through a proforma completed by a clinician prior to the diagnostic testing. They reported sensitivity and specificity of a large range of clinical features (Table 2 and Supplementary Table 3). Wet cough did not discriminate well between PCD positive and negative patients (sensitivity 0.93, specificity 0.15), because it was the main reason for referral, so was present in virtually all patients. Neonatal chest symptoms and neonatal rhinitis had a high specificity (0.83 and 0.94), but a lower sensitivity (0.27 and 0.75). The sensitivity and specificity for 25 clinical features are summarised in Table 2 and described in detail in the supplementary file.

In addition to reporting on single symptoms, Behan *et al* developed a 7-point questionnaire-based prediction tool (PICADAR), to help predict the likelihood that a patient referred for evaluation of persistent wet cough has PCD. PICADAR was internally and externally (in a second cohort) validated and is the first clinical prediction tool developed for PCD. The score ranged from 0 to 14; sensitivity and specificity of a score of >5 were 0.90 and 0.75 respectively; clearly better than single symptoms.

Shapiro *et al* analysed data from 767 consecutive paediatric and adult patients[11]. Information on situs was determined by physicians at local consortium sites through review of radiology, surgery, and cardiology reports and radiology images from participant medical records. Patients were divided into 3 situs categories: situs solitus, situs inversus and situs ambiguous (including heterotaxy).

Situs abnormalities were reported by Behan and Shapiro for a total of 1048 patients. The pooled sensitivity for the two papers (for any situs abnormality) was 0.508 and specificity 0.939 (Supplementary Table 3).

*Narrative review of additional evidence*

Leigh *et al* described a prospective cohort of 534 children with high suspicion of PCD, among whom many had a pre-existing diagnosis of PCD. Experts defined *a priori* and tested 5 clinical features, apparent in early childhood, and found 4 to be alone or in combination predictive of PCD: (1) unexplained neonatal respiratory distress with supplemental oxygen requirement more than 24 hours in term infants; (2) early-onset, year-round, wet cough; (3) early-onset, year-round nasal congestion; and (4) laterality defects [12]. Noll *et al* described a retrospective cohort of 323 patients with chronic cough referred for ciliary function analyses, and reported high specificity (>0.9) for neonatal respiratory distress (NRDS), persistent otitis media, situs inversus and bronchiectasis[13]. Chin *et al* reviewed retrospectively records of 118 patients referred for electron microscopy because of suspected PCD, and compared combinations of symptoms between patients with abnormal and normal EM, while excluding uncertain cases. They found more sino-nasal, middle ear and pulmonary symptoms in the abnormal group [11]. Beucher *et al* compared patients with abnormal and normal EM in a retrospective cohort of 89 children suspected of PCD, excluding 21 uncertain cases and found that only situs inversus differed significantly between the groups[14]. Pifferi *et al* compared clinical symptoms in 98 patients with primary PCD versus secondary ciliary dyskinesia; statistically significant differences were found for situs inversus and severity of bronchiectasis [15]. Mullowney *et al* , in the only publication that focused on neonates, compared neonatal symptoms between 46 PCD patients and 46 controls with a history of NRDS[16], and found that lobar collapse, situs inversus and prolonged oxygen need were more common in infants with PCD. The combination of situs inversus, lobar collapse, or oxygen need for >2 days had 87% (95% CI 74–94) sensitivity and 96% (85–99) specificity for PCD. A systematic review by Goutaki *et al* describes other case-control or case series studies on prevalence of clinical symptoms in PCD, which do not fulfil the inclusion criteria for this study [17]. All studies are from developed countries, and it is probable that the predictive value of some symptoms would be different depending on geographical region; for example, sensitivity and specificity of bronchiectasis will be different in sub-Saharan Africa where bronchiectasis due to TB is common.

*Key unanswered questions and research needs*

Further research is needed using prospective cohort studies of patients referred with suspicion of PCD, in whom clinical features are assessed in a standardised way before they are diagnosed. Analyses must be stratified by age. In particular, there is a need for prospective studies of neonates with NRDS. In addition, it might be helpful to combine information into clinical prediction scores, using state of the art approaches [16]. Validity of the different clinical features is also likely to vary depending on the population under evaluation. For instance, positive and negative predictive values of the symptoms depend strongly on the prevalence of the disease in the referral population and will be poorer in populations with a lower prevalence (i.e. in primary or secondary care compared to PCD referral centres). Sensitivity and specificity (shown in the table) do not depend on prevalence. Nevertheless the mix in PCD phenotypes, and therefore the usefulness of different symptoms for prediction of PCD is likely to differ between patients attending specialised clinics (e.g. ENT, pulmonology, cardiology). For instance, while chronic cough will not distinguish between patients with and without PCD in a pulmonology clinic, chronic ENT symptoms will not be distinctive in an ENT clinic, where (nearly) every patient has these complaints, and cardiac defects will not distinguish in a cardiology setting. Another factor to consider is that clinical features might differ between genetic variants (e.g. patients with CCNO variants show no situs anomalies but increased female infertility), so results vary with differences in prevalence of specific mutations in the evaluated population. Studies therefore must be done in specific health care settings and study populations, and consider age groups, sex, and genetic abnormalities.

*Summary*

Relevant literature answering our question was extremely scarce (two papers only, of which one reported only on situs inversus), and results did not allow to take severity of symptoms into account or stratify by age. Overall confidence in their results is moderate mainly because diagnostic performance does not inform downstream consequences of further clinical management based on the assessment of these symptoms.

Results suggest that clinical symptoms may help to distinguish between patients with and without PCD, but the positive predictive value (how many patients with a specific symptom do have the disease) of single symptoms is low. Instead, the combination of suggestive symptoms might discriminate better, but this needs further studies in different populations.

Wet cough starting in early childhood has been used as the initial selection criterion in most PCD studies. Therefore it has a low discriminative value due to its high prevalence in both PCD positive and negative individuals recruited to these studies.

Nasal Nitric Oxide

Summary of recommendations

In patients suspected of having PCD, should nasal nitric oxide be used as a diagnostic tool?

Based on MODERATE confidence in the evidence, we recommend that:

1. Nasal nitric oxide measurement should be used as part of the diagnostic work-up of schoolchildren over 6 years and adults suspected of having PCD, preferably using a chemiluminescence analyser with a velum closure technique (strong recommendation).
2. In children under 6 years suspected of having PCD, we suggest nasal nitric oxide measurement using tidal breathing as part of the diagnostic work-up (weak recommendation).

Remark - we suggest that patients presenting with a strong clinical history should undergo further testing, even if nNO is normal (weak recommendation)

*Explanation of the diagnostic test*

Nasal nitric oxide (nNO) is extremely low in PCD when compared to healthy and disease controls, for unknown reasons [19]. The accuracy of nNO as a diagnostic test in PCD varies by type of analyser, sampling method and age of patient [20].

Current guidelines recommend aspiration of gas from one nostril with gas entrained via the other naris to measure nNO using a stationary chemiluminescence analyser during a velum closure, such as breath hold or oral exhalation against resistance. The reading should be obtained from a technically acceptable plateau reading[21]. Whilst measurement during velum closure by chemiluminescence analyser is considered the ‘gold standard’, this manoeuvre is not possible in all situations. In young children measurements during tidal breathing have been reported[22, 23]. Electromechanical portable analysers [23] are used where stationary chemiluminescence analysers are not available. There is currently no consensus over what threshold constitutes a positive or negative cut-off.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Publication** | **Study population (n=)** | **Sampling method**  **(n, threshold nl/min)** | **Sensitivity (95% CI)** | **Specificity (95% CI)** |
| Marthin *et al* 2011 [24] | 117 referrals  PCD 14 | Breath hold (n=58, 52.5)  Oral exhalation against resistance (n=37, 72.6)  Tidal breathing (n=97, 47.4) | 0.92 (0.62 to 0.998)  1.0 (0.54 to 1.0)  0.93 (0.66 to 0.998) | 0.96 (0.85 to 0.995)  0.94 (0.79 to 0.99)  0.80 (0.69 to 0.88) |
| Leigh *et al* 2013[25] | 155 referrals  PCD 71  Indeterminate 84 | Oral exhalation, velum closure  (n=155, 77 ) | 0.99 (0.92 to 0.9996) | 0.75 (0.64 to 0.84) |
| Beydon *et al* 2015[22] | 86 referrals  PCD 49  Non-PCD 37 | Velum closure (n=74, 82.2 )  Tidal breathing – 5 peaks (n=86, 40) | 0.91 (0.79 to 0.98)  0.90 (0.78 to 0.97) | 0.86 (0.68 to 0.96)  0.97 (0.86 to 0.999) |
| Jackson *et al* [26] | 301 referrals  PCD 34  Non-PCD 267 | Velum closure (breath hold or oral exhalation)  (n=301, 30) | 0.90 (0.74 to 0.98) | 0.95 (0.90 to 0.98) |

Table 3. Summary of diagnostic accuracy of nasal nitric oxide (nNO) from measurements in consecutive patients suspected of PCD.

Although analysers report readings in parts per billion (ppb), this is influenced by the machine sampling rate, so the concentration is converted to nanolitres/min (nl/min) by the formula nl/min=ppb x sampling rate in l/min.

*Review of evidence directly addressing the question “in patients suspected of having PCD, should nNO be used as a diagnostic tool?”*

Our search identified 98 studies, of which 23 met inclusion criteria for qualitative assessment. Of these, four papers (n=588 patients) assessed nNO in a cohort of patients suspected of PCD who eventually received either a positive or negative diagnosis, directly addressing the question (Table 3 and Supplementary Table 4). The other 19 papers were excluded from informing the recommendations but contributed to the narrative review (Supplementary Table 5).

Marthin *et al*. measured nNO during breath hold, exhalation against resistance and tidal breathing. Sensitivity ranged from 0.92 (for breath hold) to 1.0 (oral exhalation against resistance) and specificity ranged from 0.80 (tidal breathing) to 0.96 (breath hold)[24]. Leigh *et al* developed a threshold of 77nl/min using data from a PCD specialist centre and then trialled this cut-off in 155 consecutive patients at other sites. Comparing PCD positive to indeterminate patients provided a sensitivity of 0.99 and specificity of 0.75[25]. Lower specificity was because the diagnostic protocol only included electron microscopy and genetics, thus missing a number of true PCD cases (‘indeterminate’ rather than PCD negative). Beydon *et al* reported a sensitivity of 0.91 and specificity of 0.86 for velum closure (cut-off 82nl/min) and 0.90 and 0.97 for tidal breathing (40nl/min; mean of 5 peaks)[22]. Jackson *et al* used a cut-off of 30nl/min, and reported sensitivity of 0.91 and specificity of 0.96 to distinguish 34 PCD positive from 267 PCD negative patients[26]. Further methodological details of these 4 studies are included in Supplementary Table 4.

Overall confidence in this evidence is moderate mainly because diagnostic performance is not informative of downstream consequences of further clinical management

*Narrative review of additional evidence*

A number of studies that did not meet the inclusion criteria for making recommendations addressed important issues. Several studies used alternative methods for nNO measurement that do not use the ATS/ERS guideline “gold standard” (velum closure, stationary analyser) [21]. Tidal breathing manoeuvres are useful, especially in those unable to perform a velum closure, but may be less discriminative. Marthin *et al’s* study of consecutive referrals found breath hold sensitivity of 0.92 and specificity of 0.96 compared to tidal breathing values of 0.93 and 0.80 (thresholds were breath hold – 52.5nl/min, tidal breathing – 47.4nl/min)[23]. Beydon *et al*, however, found increased accuracy of tidal breathing (37.9nl/min threshold; sensitivity 0.94, specificity 0.92) versus velum closure (82.2nl/min, 0.91, 0.86)[22]. Measurement using portable analysers was assessed in two case control studies. Using a portable analyser, Marthin *et al* compared PCD patients to those with CF and healthy controls. They found a 1.0 sensitivity and 0.95 specificity for breath hold (64nl/min threshold) and 1.0/1.0 for tidal breathing (43nl/min) [23]. Harris *et al* studied 13 PCD and 37 disease control/healthy patients using tidal breathing and a portable analyser with a cut off of 30nl/min. Sensitivity was 1.0 and specificity 0.95[27].

Measurement of nNO in young children is possible, however discrimination between PCD patients and controls is reduced as nNO is inversely proportional to age in healthy patients under 12 years[28, 29]. One study showed that velum closure was possible in children as young as 3.9 years [20]. However the majority of very young children are unable to co-operate with velum closure and so tidal breathing measurements have to be used. The studies by Marthin *et al* and Beydon *et al* suggest that tidal breathing may produce similar accuracy to velum closure in adults[22, 23], however this has not been shown in children; Marthin *et al’s* study of 117 consecutive referrals of all ages, found that the false positive rate for children under 6 years using tidal breathing was 39%[23].

There is increasing evidence that some genetic defects causing PCD with subtle beating defects may be associated with nNO levels within the normal range. This includes two studies of PCD individuals with mutations encoding radial spoke head proteins and one in PCD individuals with abnormal nexin link composition due to GAS8 mutations associated with nNO higher than that usually seen in PCD [30–32]. This may partially explain the variability of the results and low diagnostic performance of nNO in some studies

*Key unanswered questions and research needs*

Current evidence has shown that nNO is a useful test as part of the diagnostic process, however there is no consensus on appropriate thresholds. Likewise, standardised protocols and thresholds need to be developed for tidal breathing, portable analysers and measurements and normative data in younger children, particularly those under 6 years of age. Further work on genotype-phenotype correlation can help in interpretation of nNO levels in cases of diagnostic uncertainty in order to reduce the number of false negative test results. There is no evidence that can lead us to recommend which patients with a normal nNO should be referred for further testing and this requires evaluation.

*Summary*

Nasal NO is a highly accurate test for PCD when measured via stationary chemiluminescence analyser using velum closure techniques with a sensitivity of 0.90-1.0 and specificity of 0.75-0.97. Tidal breathing technique or use of portable analysers are less sensitive and specific but may contribute to the diagnostic decision. Different studies have used different methods and cut-off values making it difficult to provide definite thresholds.

Nasal NO is not sufficiently accurate to rule in or rule out PCD in isolation but considering that it is relatively easy to perform, non-invasive and affordable, the panel considered that it should be used as part of the diagnostic work-up of patients suspected of having PCD.

High Speed Video Analysis

Summary of recommendations

In patients suspected of having PCD, should HSVA be used as a diagnostic tool?

Based on LOW confidence in the evidence, we recommend:

1. High speed video analysis, including ciliary beat frequency and beat pattern analysis, should be used as part of the diagnostic work-up of patients suspected of having PCD (weak recommendation).
2. Ciliary beat frequency should not be used without assessment of ciliary beat pattern in diagnosing PCD (strong recommendation).

To improve diagnostic accuracy of HSVA, CBF/P assessment should be repeated after ALI culture (strong recommendation).

*Explanation of the test*

PCD is related to abnormal ciliary function [33] which can be analysed ex-vivo by assessment of ciliary activity in respiratory epithelium from the nose or bronchus. Ciliated cells can be observed immediately after sampling[34–36] and again after a period of culture to differentiate PCD from secondary dyskinesia [37–40]. A video attached to a microscope records at high speeds (120 to 500 fps), and is replayed slower (30-60fps) to review ciliary beat pattern (CBP) and measure ciliary beat frequency (CBF)[41]. Most studies have used analysis by expert microscopists, whilst several studies used computer analysis in an attempt to reduce subjectivity/ observer bias. High speed video analysis (HSVA) provides a permanent record that can be used for audit, expert advice, or research.

*Review of evidence directly addressing the question “in patients suspected of having PCD, should HSVA be used as a diagnostic tool?”*

Our search identified 113 studies, of which 30 met inclusion criteria for qualitative assessment. (Supplementary Figure 1). Two studies (n=650 patients) assessed HSVA in cohorts suspected of PCD who eventually received either a positive or negative diagnosis, contributing to the evidence for recommendations (Table 4). The other 28 papers did not meet the inclusion criteria for informing the recommendations, but contributed to our narrative review (Supplementary Table 6).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Publication** | **Study population** | **Cilial assessment method** | **Sensitivity (95% CI)** | **Specificity (95% CI)** |
| Papon *et al* 2012 [42] | 25 referrals  (10 PCD positive) | HSVA beat frequency and quantitative measurements of beat pattern | 0.96 (0.89-0.98) | 0.95 (0.91-0.98) |
| Jackson *et al* 2015 [26] | 625 referrals  (60 PCD positive) | HSVA beat frequency and subjective pattern | 1.0 (0.94-1.00 ) | 0.93 (0.91-0.95) |

Table 4. Summary of diagnostic accuracy of high-speed video analysis (HSVA) from evaluation in consecutive patients suspected of PCD. Two studies fitted the PICO and inclusion criteria.

Papon *et al*. measured 12 parameters of ciliary beat pattern, including ciliary beat frequency. The distance travelled by the cilia tip weighted by the percentage of beating edges had the best sensitivity (0.96) and specificity (0.95) to distinguish 10 PCD positive from 15 PCD negative patients [42]. Using this parameter in 9 patients with previously inconclusive diagnoses, it was possible to support the diagnosis of PCD in 4 cases and exclude it in 2. Jackson *et al.* found a sensitivity of 1.00 and specificity of 0.93 for the combination of ciliary beat frequency measurement and beat pattern evaluation in a cohort of 625 referrals, including 60 PCD positive [26].

Overall confidence in this evidence is low mainly because diagnostic performance is not informative of downstream consequences of further clinical management based on the assessment of HSVA and because of study limitations (HSVA was widely used as part of the reference standard and lack of blinding).”

*Narrative review of additional evidence*

To date, there is no standardised method for cell processing and analysis. Respiratory epithelium can be collected using brush, curette or forceps, usually from the nose[43]. Ciliary function varies under differing conditions, for example temperature and pH, with some centres measuring at 37oC[26, 40, 42, 44] and others at lower temperatures[35, 37, 45]. This will affect ciliary function and all centres need to define their own normative data until a consensus is reached to allow standardisation of methods and reporting between centres.

Equivocal results or abnormal results require repeat sampling or reanalysis following cell culture [38, 40, 46, 47] since secondary defects are common. In a series of 712 patients, Jorissen *et al* assessed CBF and ciliary coordination in suspension culture (i.e. spheroids). Twenty percent of non-PCD (n=642) patients demonstrated abnormal ciliary activity before culture, but after culture 100% had normal ciliary activity. Conversely, in biopsies of PCD patients (n=70; evaluable in 56), 20% had a normal CBF and 10% had a coordinated ciliary activity before culture. After culture, a normal CBF was found in 7% of PCD patients but ciliary function was never normally coordinated, making this parameter more sensitive and specific than CBF measurement [47]. Hirst *et al* report CBF and CBP before and after air-liquid interface (ALI) cultures in 158 patients [40]. Before culture, most PCD and non-PCD patients exhibited a degree of functional ciliary abnormalities. After ALI-culture, normal CBP was observed in all non-PCD patients whilst in PCD patients, CBP was uniformly abnormal. Pifferi *et al* assessed the results of CBP and CBF analysis after suspension culture (i.e. spheroids) in 9 subjects with inconclusive results on nasal brushings [36]. After culture, 4 patients had abnormal CBP suggesting PCD diagnosis, 2 had secondary dyskinesia CBP and 3 remained inconclusive. Culture techniques are limited by success rates ranging from 54-83% [26, 37, 40].

CBF measurement does not adequately differentiate PCD from non-PCD unless combined with CBP assessment. Stannard *et al* found a sensitivity of 0.97 and a specificity of 0.95 for the percentage of dyskinetic epithelial edges whilst CBF alone only yielded a sensitivity and specificity of 0.87 and 0.77[48]. Moreover, CBF may be slow, normal or increased in PCD depending on the genotype[49].

Some ultrastructural defects and genetic mutations causing PCD may be associated with specific patterns of ciliary beating. In a cohort of 56 children, Chilvers *et al* reported virtually immotile cilia in patients with either a combined IDA and ODA defect or an isolated ODA defect, stiff beat pattern in patients with either an isolated IDA or radial spoke with an IDA defect, and circular beating cilia in patients with a ciliary transposition defect[44]. Raidt *et al* studied CBP according to the genetic variants of PCD[49]. Although numbers associated with some genes were extremely small, the data supports the linking of PCD causing-gene with particular CBPs: for cilia from patients with mutations in ODA causing genes (*DNAH5, DNAI1, DNAI2, ARMC4*), showed minimal residual movements. In patients with DNAH11 mutations (normal ultrastructure), cilia exhibited a hyperkinetic CBP with reduced proximal axonemal bending. Some genetic defects such as GAS8 mutations can result in so subtle defects hardly detectable by HSVM [30].

*Key unanswered questions and research needs*

Current evidence suggests that HSVA is a useful test as part of the diagnostic process, but there is no consensus on appropriate cell processing and method of ciliary assessment. Likewise, standardised protocols and thresholds need to be developed for *ex vivo* analysis of ciliary beat pattern. Further work on genotype/ultrastructural-phenotype correlation can help in interpretation of HSVA parameters in cases of diagnostic uncertainty.

*Summary*

HSVA is an accurate test for PCD when performed by experienced observers combining ciliary beat frequency measurement and pattern analysis (sensitivity of 0.95-1.00 and specificity of 0.93-0.95). Culturing the respiratory cells may contribute to improve the accuracy of HSV, in particular to rule out false positives.

HSVA is not sufficiently standardised to rule in or rule out PCD in isolation. Considering that optimal conditions in functional evaluation of cilia remains to be defined, the panel considered that HSVA should be performed by experienced staff as part of the diagnostic work-up of patients suspected of having PCD. This might impair the availability of the test in many centres.

Transmission Electron Microscopy

Summary of recommendations

In patients suspected of having PCD, should TEM be used as a diagnostic tool? Based on LOW confidence in the evidence, we recommend:

1. Ciliary ultrastructure analysis by transmission electron microscopy should be used as part of the diagnostic work-up of patients suspected of having PCD (strong recommendation).
2. Further diagnostic investigations should be performed in patients with normal ultrastructure if the clinical history is strong (strong recommendation).1
3. In patients with hallmark ciliary ultrastructure defects for PCD further confirmatory diagnostic investigations are not required2. (strong recommendation)

Footnote: 1normal ciliary ultrastructure, as resolvable by transmission electron microscopy, does not exclude the diagnosis of PCD (16% PCD positive patients have TEM without a detectable defect);. 2patients with hallmark ciliary ultrastructure defects for PCD (absence of outer dynein arms, combined absence of inner and outer dynein arms, inner dynein arm absence combined with microtubular disarrangement), assessed by TEM, almost always have PCD (false positive results are very rare ≈0.7%)

*Explanation of the diagnostic test*

In 1976 Afzelius *et al* demonstrated that transmission electron microscopy (TEM) could be used to detect ultrastructural defects of cilia in patients with primary ciliary dyskinesia[33]. For many years subsequently TEM was considered the ‘gold standard’ diagnostic test for PCD. However, several genetic studies have demonstrated that an increasing number of distinct genetic PCD sub-types (e.g. due to DNAH11 mutations) cannot be diagnosed by TEM [50]. Thus, TEM cannot rule out PCD diagnosis.

Respiratory epithelium is usually sampled from the inferior turbinate of the nose by brush or curette biopsy or from the lower respiratory tract during bronchoscopy. The epithelium is chemically fixed with glutaraldehyde, processed and embedded into blocks which are sectioned with an ultramicrotome. Staining with heavy metals (lead and uranyl) provides contrast. Assessment of cilia from healthy cells in transverse section is made using a transmission electron microscope[51, 52]. The number of cilia and cells analysed varies between centres; unless sufficient numbers are assessed, defects caused by mutations in genes which cause intermittent defects are likely to be missed. Considerable expertise is required to perform TEM and interpret results; expenditure for equipment and running costs are high.

The normal ultrastructural ciliary arrangement in transverse section is a circle of nine microtubule doublets, each with a pair of dynein arms, plus a central pair of microtubules (Figure 1). There are a number of ultrastructural phenotypes associated with a diagnosis of PCD. The majority of cases are due to a lack of dynein arms; other defects include disorganisation of the microtubular doublets or loss of the central microtubular pair (Table 6). Some patients with PCD have apparently normal ciliary ultrastructure, as resolvable by TEM. Secondary ciliary dyskinesia can be associated with transient ultrastructural abnormalities, such as compound cilia, axonemal blebs or additional tubules, which must not be confused with PCD.

**Figure 1:**  Diagram of normal ultrastructure of the ciliary axoneme in transverse section

**Figure 2:** Electron microscopy images of PCD defects. A. Inner and outer dynein arm defect, B. Outer dynein arm defect, C. Inner dynein arm and microtubular disarrangement, D. central pair and transposition defect

*Review of evidence directly addressing the question “in patients suspected of having PCD, should TEM be used as a diagnostic tool?”*

We identified and screened 370 studies, of which 46 full texts were assessed for eligibility. Of the 17 that met inclusion criteria for qualitative assessment (Supplementary Table 7), 11 papers (n=3200 patients) assessed TEM in a cohort of patients suspected of PCD who eventually received either a positive or negative diagnosis, contributing to the evidence for recommendations (Supplementary figure 1).

Tables 5 & 6 summarise the 11 studies addressing the question. The sensitivity calculated from each study ranged between 0.71 and 1.00 and the specificity between 0.92 and 1.00. There were five false positive patients in two studies. Papon *et al* identified two false positive results; one was a child with severe asthma without recurrent upper airway infection who had short or absent ODA concerning 44% of nasal cilia and 90% of bronchial cilia, the other an adult with situs inversus and nasal polyposis without lower airway symptoms who had absent IDA without microtubular disorganisation (pers comm). Munkholm *et al* identified three false positives in individuals each eventually thought to have a secondary ciliary dyskinesia, two of whose clinical phenotype improved becoming asymptomatic and a third who had severe asthma [53]. Total specificity, when combining all 11 studies, was >0.99.

Quality of evidence was rated low because diagnostic performance is not informative of downstream consequences of further clinical management and because of study limitations (frequent use of TEM in the reference standard and lack of bliniding). However, the very low rate of false positives and the very high specificity of TEM led to strong recommendations.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Publication** | **Study Population (n)** | **Conclusive diagnostic result reached (n)** | **Sensitivity**  **(95% CI)** | **Specificity**  **(95% CI)** |
| Jorissen *et al* 2000 [37] | 812 | 468 | 0.71 (0.61-0.81) | 1.0 (0.99-1.0) |
| Pifferi *et al* 2007 [54] | 64 | 62 | 0.75 (0.48 -0.93) | 1.0 (0.93-1.0) |
| Pifferi *et al* 2009 [39] | 59 | 56 | 0.77 (0.50 -0.93) | 1.0 (0.91-1.0) |
| Hirst *et al* 2010 [55] | 231 | 187 | 1.0 (0.88-1.0) | 1.0 (0.98-1.0) |
| Papon *et al* 2010 [56] | 1149 | 793 | 0.82 (0.77-0.86) | 1.0 (0.99-1.0) |
| Olm *et al* 2011 [57] | 24 | 24 | 0.92 (0.62-1.0) | 1.0 (0.74-1.0) |
| Papon *et al* 2012 [42] | 34 | 28 | 0.83 (0.52-0.98) | 1.0 (0.79-1.0) |
| Shoemark *et al* 2012 [58] | 1182 | 1031 | 0.88 (0.83-0.91) | 1.0 (1.0-1.0) |
| Hirst *et al* 2014 [40] | 165 | 122 | 0.96 (0.87-1.0) | 1.0 (0.95-1.0) |
| Munkholm *et al* 2015 [53] | 239 | 61 | 0.83 (0.61-0.95) | 0.92 (0.79-0.98) |
| Jackson *et al* 2015 [26] | 868 | 368 | 0.79 (0.68-0.88) | 1.0 (0.99-1.0) |

Table 5. Sensitivity and specificity of the 11 studies directly addressing the PICO question using transmission electron microscopy to diagnose PCD

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Papon *et al*, 2010 [56]  n=190 | Stannard *et al*, 2010 [48]  n=68 | Olin *et al*, 2011 [59]  n=155 | Shoemark *et al*, 2012 [58]  n=214 | Boon *et al*, 2014 [60]  n=138 | Jackson *et al*, 2015 [26]  n=57 | **Total** |
| Isolated outer dynein arm defect | 33% | 26% | 54% | 41% | 59% | 46% | **44%** |
| Inner and outer dynein arm defect | 32% | 34% | 23% | 24% | 6% | 39% | **25%** |
| Inner dynein arm with microtubular disorganisation | 13% | 6% | 7% | 9% | 16% | 9% | **10%** |
| Isolated Inner dynein arm defect | 4% | 21% | 15% | 13% | 0% | 0% | **9%** |
| Central pair defect | 19% | 13% | 1% | 12% | 14% | 7% | **8%** |
| Other\* |  | 3% |  |  | 5% |  | **1%** |
| Total (n=) | 190 | 68 | 155 | 214 | 138 | 57 |  |

Table 6: Characteristics of the ultrastructural defects described in 9 studies directly addressing the PICO question using transmission electron microscopy to diagnose PCD. \* Other defects reported include ciliary aplasia, disorientation and extra microtubules

*Narrative review of additional evidence*

Assessment of the proportion of TEM defects in patients with PCD was made following review of all manuscripts (post 1996) describing a cohort of more than fifty individuals [26, 42, 48, 58–60] (Table 4). Outer dynein arm defects (26-59%) and combined outer and inner dynein arm defects (6-39%) were the most commonly observed. The recommendations below refer to common hallmark defects (absence of outer dynein arms, combined absence of inner and outer dynein arms, inner dynein arm absence combined with microtubular disarrangement). Isolated inner dynein arm defects by TEM are controversial. Several studies acknowledge that inner dynein arms are difficult to visualise by TEM [42, 61, 62]and repeat analysis has been recommended before confirming a diagnosis [63]. For central pair defects the ciliary defect is usually present in a minority of cilia making the diagnosis difficult especially since patients do not have situs inversus.

Evidence for add on techniques to improve electron microscopy in the diagnosis of PCD was reviewed. Computer-assisted analysis has been reported to enhance the visualisation of dynein arms and consequently improve the sensitivity of electron microscopy [61, 62]. Electron tomography is an advanced TEM technique allowing visualisation of structures in three dimensions. A series of transmission electron microscopy images are acquired by tilting the specimen stage at regular increments around two perpendicular axes. Images from both tilt series are then aligned into a single three-dimensional high-resolution projection. If a structural feature is repeated within a tomogram, it can be enhanced through sub-tomographic averaging; a technique in which software extracts the chosen common features and makes comparison by cross-correlation. Electron tomography has been shown to improve 3D visualisation and resolution of cilia allowing identification of patients with *HYDIN* and *DNAH11* gene defects in a research setting [64]. The use of tomography for diagnosis has not been evaluated.

Our evidence review considered only conclusive results. Reported rates of inconclusive results ranged from 1.7% to 28.6% [26, 37, 39, 58]. This was attributed to poor sampling technique or the presence of secondary changes to the cilia. Seven of the 11 studies reported measures to avoid sampling during or immediately after an upper respiratory tract infection to improve adequacy and minimise secondary ciliary ultrastructural change.

Cell culture techniques that induce ciliogenesis from human biopsies are used in a number of PCD diagnostic centres. Two techniques to induce basal cell proliferation and ciliated cell differentiation have been described for PCD diagnosis[37, 40]. Jorissen *et al* established a submerged culture technique [37] and the air-liquid interface technique was first described for PCD diagnosis by Hirst *et al*[40]. Both methods have shown that the TEM axoneme structure is conserved after cell culture in normal and PCD subjects, and they have been shown to reduce secondary damage [37, 40]. TEM following culture has the potential to aid diagnosis of reduced generation of multiple motile cilia [65].

*Key unanswered questions and research needs*

Basic science research must improve the TEM technique and identify PCD in those with ‘normal ultrastructure’. The diagnostic community requires standardised protocols and consensus on terminology, especially regarding the number and proportion of cilia required to make a diagnosis. True relevance and prevalence of inner dynein arm and other rare defects needs confirming.

*Summary*

Transmission electron microscopy is a highly specific test to confirm a diagnosis of PCD and is a key part of the diagnostic work. However, some patients with PCD have apparently normal ultrastructure and therefore TEM should not be used in isolation to exclude a diagnosis.

All 11 studies were retrospective analyses of cohorts of patients with clinical suspicion of PCD, the largest of which spanned time periods of twenty years[56, 58]. Further downgrading was due to use of TEM as the reference standard and lack of blinding, resulting in grading of evidence as low.

Genetics

In patients suspected of having PCD, should genotyping be used as a diagnostic tool?

There were no studies that fulfilled inclusion criteria to answer this question.

*Explanation of the diagnostic test*

PCD is a genetically heterogeneous disorder. As with autosomal recessive disorders in general, disease is more likely in offspring from consanguineous relationships, and has a 1:4 probability from any conception where both parents are healthy carriers. To date, mutations in more than 30 genes have been reported to cause PCD (Table 7). A more detailed explanation of the PCD-associated genes is presented in the supplementary file.

|  |  |  |  |
| --- | --- | --- | --- |
| **Gene** | **Locus** | **TEM finding** | **IF finding** |
| *DNAH5* [66] | 5p15 | ODA | Absent DNAH5 and DNAH9. [67–69] |
| *DNAH11* [50] | 7p15-21 | Normal | DNAH11 is absent in patients with DNAH11 loss-of function mutations. DNAH5 and DNALI1 present [70, 71] |
| *DNAI1* [72] | 9p21-p13 | ODA | DNAH5 staining may be present proximally but absent distally.  DNAH9 absent within the ciliary axonemes. [67, 68] |
| *DNAI2* [68] | 17q25.1 | ODA | DNAH5, DNAI2 and DNAH9 absent or aberrant [68] |
| *NME8 (TXNDC3)* [73] | 7p14.1 | ODA | Not reported |
| *DNAL1* [74] | 14q24.3 | ODA | Not reported |
| *CCDC151* [75] | 19p13.2 | ODA | DNAH5, CDC151, CCDC114 and ARMC4 absent; DNALI1 present. [75] |
| *CCDC114* [76] | 19q13.33 | ODA | CCDC114 severely reduced, DNAH5 absent, DNALI1 undisturbed [76] |
|
| *ARMC4* [77] | 10p21 | ODA | Reduced ARMC4 staining along cilia; complete distal loss of DNAH5; DNAH5 only on proximal ciliary end; DNALI1 present. [77, 78] |
| *CCDC103* [79] | 17q12 | ODA+IDA | DNAH5, DNAH9 and DNALI1 are missing or reduced in a small number of patients. [79] |
| *DYX1C1 (DNAAF4)* [80] | 15q21 | ODA + IDA | DNAH5, DNAH9 and DNAI2 absent [80] |
| *SPAG1* [81] | 8q22 | ODA + IDA | Absent DNAH5 and DNALI1 [81] |
| *LRRC6* [82] | 8q24 | ODA + IDA | LRRC6, DNALI1 and DNAI2 absent or very reduced [82–84] |
| *DNAAF2 (KTU)* [85] | 14q21.3 | ODA + IDA | DNAH5 and DNAI2 absent distally with some residual staining.  DNAH9 and DNALI1 absent.[85] |
| *DNAAF1 (LRRC50)* [86, 87] | 16q24 | ODA + IDA | DNAH5, DNAH9 and DNALI1, absent [87] |
|
| *C21orf59* [88] | 21q22.1 | ODA + IDA | Absent DNAH5 and DNALI1[88] |
| *DNAAF3* [89] | 19q13 | ODA + IDA | DNAH5, DNAH9 and DNALI1 absent [89] |
| *ZMYND10* [84] | 3p21.3 | ODA + IDA | Absent DNAH5, DNAI2 and DNALI1.[84, 90] |
| *DNAAF5 (HEATR2)* [91] | 7p22.3 | ODA + IDA | DNAI1, DNAH5 and DNALI1 absent, HEATR2 reduced [91, 92] |
| *HYDIN* [93] | 16q22 | Normal/ subtle: increased frequency of transposition defects | Normal IDA (DNALI1) and ODA (DNAH5) [93] |
| *RSPH1* [32] | 21q22.3 | Intermittent central pair/ transposition defects | RSPH1 and RSPH9 absent; RSPH4A present [32, 94, 95] |
| *RSPH3* [96] | 6q25.3 | Intermittent central pair/ near absence of radial spokes | RSPH3 and RSPH11 absent; RSPH1, RSPH4A, and RSPH23 present (RSPH9 not reported). DNALI1 present. [96] |
| *RSPH9* [94] | 6p21 | Intermittent central pair defect/ transposition | Absent RSPH9; RSPH1 and RSPH4A present. [94] |
| *RSPH4A* [94] | 6q22 | Intermittent central pair defect/ transposition | Absent RSPH4A, RSPH9 and RSPH1. [94] |
| *DRC1 (CCDC164)* [97] | 2p23 | Normal/ subtle: N-DRC links missing with occasional MT disorganisation | GAS8 and LRRC48 absent from ciliary axonemes. [97] |
| *GAS8 (DRC4)*[30] | 16q24.3 | Normal/ subtly abnormal: increased frequency of MT misalignment | DNALI1 and DNAH5 present; absent GAS8 [30] |
| *CCDC65 (DRC2)* [98] | 12q13.12 | Normal/ N-DRC links missing with occasional MT disorganisation | CCDC65 and GAS8 reduced[98] |
| *CCDC39* [99] | 3q26 | MT disorganisation + IDA | Absent CCDC39 protein. ODA normal distribution (DNAH5, DNAI2, DNAH9); DNALI1 (IDA) absent; GAS8 in cytoplasm but absent from axoneme [99, 100] |
| *CCDC40* [101] | 17q25 | MT disorganisation + IDA | Absent CCDC39 protein; RSPH4A and ROPN1L/RSP11 present in axonemes [100, 101] |
| *RPGR#*[102] | Xp21.1 | Variable | Normal, DNAH5 and DNALI1 present [103] |
| *OFD1\** [104] | Xp22 | Unknown | Not reported |
| *CCNO* [65] | 5q11.2 | Reduction of cilia number | DNAH5 present; rootletin mislocated in deeper regions of cytoplasm; CCNO not detectable [65] |
| *MCIDAS* [105] | 5q11.2 | Reduction of cilia number | MCIDAS, CCNO, DNAH5, CCDC39 and CCDC78 absent [105] |

Table 7: Overview of PCD-causing genes, and their associated findings by TEM and IF analyses. ODA: outer dynein arm; IDA: inner dynein arm; n-DRC: nexin link- dynein regulatory complex; #: retinitis pigmentosa usually detected in adult patients; \*: rare syndromic phenotype

To establish the genetic diagnosis, non-ambiguous biallelic mutations in autosomal recessive PCD and hemizygous mutations in X-linked PCD should be identified. The majority of reported mutations are nonsense, frameshift or splice mutations while missense mutations are identified in a minority of cases. Most of the mutations are private, but founder mutations (e.g. in *DNAI1*[106] and *DNAH5*[69]) and mutational hot spots (e.g. *CCNO*[107]) have been reported. The ranking of the effect of the mutations should follow international recommendations [108]: benign (class 1), likely benign (class 2), unknown significance (class 3), likely pathogenic (class 4), pathogenic (class 5).

The associations between genotype and structural defects documented by TEM and/or IF are well established, but much less is known about gene: HSVA associations. With studies based on small numbers of patients and often limited number of videos per patient[49], there is insufficient data to correlate mutations within a gene with dyskinesia phenotype; our knowledge to date suggests that disease-causing mutations in DNAH5 are always associated with predominantly static cilia whilst mutations in different regions of DNAH11 can lead to either static cilia or hyper-frequent, stiff cilia [49, 109]. Therefore, to confirm the genetic cause of PCD, the ultrastructural defect and gene should correlate; in the future, we may be able to use gene mutation: ciliary pattern correlations as further support.

In principle all DNA sequencing technologies can be applied for genetic testing in patients with a confirmed PCD or a high suspicion of PCD (further detailed in the supplementary file). However, due to the high number and the huge size of PCD genes high-throughput techniques are now widely used. The yield of allele-specific approaches is low in PCD given the high genetic and allelic heterogeneity. Detected mutations should be confirmed by Sanger sequencing and checked for segregation in the parents. Genetic laboratories have to be aware that large heterozygous genomic deletions have been reported in PCD individuals that might be missed by DNA sequencing technologies. Homozygous and heterozygous intragenic large duplications and deep intronic mutations are also missed by sequencing techniques. The detection of intragenic deletions and duplications will benefit from the fine set up of targeted next generation sequencing (NGS) panels; however, this approach requires specific development and sensitivity assessment. All techniques, especially the second line approaches, benefit from the knowledge of the ultrastructural defect of the patient in order to assess the relevance of the molecular findings. The ≈30 PCD genes implicated to date encompass more than 700 exons and thus it is not unusual to identify a heterozygous variant in a gene that is obviously not responsible for the disease of the patient based on ultrastructural data. Cell and whole organism models can be used to confirm that a gene is disease-causing.

*Review of evidence directly addressing the question “in patients suspected of having PCD, should genotyping be used as a diagnostic tool?”*

Searches identified 462 studies, of which 95 met inclusion criteria for qualitative assessment (Supplementary Table 8). Most studies included patients with confirmed PCD with the aim of identifying novel genes rather than diagnostic cohorts. There were no studies that fulfilled the inclusion criteria for quantitative assessment.

*Narrative review of additional evidence*

In populations with confirmed or highly suspected PCD diagnosis, it is possible to identify genetic causation in 50-75% of cases [110, 111]. The sensitivity of genetic testing as a first line diagnostic test for PCD is currently unknown but is likely to be low. With the identification of further PCD genes and high-through put sequencing technologies, PCD genetic testing as “stand alone” test might be considered in the future. Genotyping is useful in instances where confirmation of the diagnosis is difficult by other approaches (e.g. *DNAH11*, *CCNO*, *MCIDAS* and *RSPH* genes mutations). The detection of bi-allelic disease-causing mutations in autosomal recessive PCD or hemizygous mutations in X-linked PCD is highly specific.

Most studies to identify novel PCD gene defects used ultrastructural defects detected by routine TEM as the starting point for the genetics search, therefore the likelihood to identify mutations in PCD with ultrastructural defects is higher than in PCD devoid of ultrastructural defects. This underscores the need not to rely on TEM as the sole diagnostic test for PCD.

Reports of mutations in specific genes typically relate to small numbers of patients and are not necessarily ethnically representative; the contribution of each gene should therefore be interpreted with caution. Studies testing for *DNAH5* and *DNAI1* mutation suggest that these mutations account for ~50-70% of cases of ODA defects[67, 69, 112, 113]. Mutations in *CCDC39* or *CCDC40*[99–101, 114]account for almost all PCD individuals with microtubular disorganisation and absence of IDA. Of 58 unrelated PCD patients with normal ultrastructure 22% had biallelic mutations in *DNAH11*[70]. Mutations in the genes encoding radial spoke head and stalk proteins (RSPH1, RSPH3, RSPH4A, RSPH9), HYDIN and nDRC proteins (DRC1, CCDC65, GAS8) can cause PCD with normal or subtly abnormal ultrastructure (Table 7); to date, the contribution of these genes to the prevalence of PCD has not been determined.

A systematic population-based genetic Israeli study revealed that RGMC may be more frequent (6%) in their particular PCD populations than previously estimated [107].

Genetic analyses have shown that mutations in the RGMC genes *CCNO* and *MCIDAS* as well as the genes encoding radial spoke proteins (RSPH1, RSPH3, RSPH4A, RSPH9) and the CP associated protein HYDIN do not result in laterality defects. In addition so far all PCD individuals carrying biallelic mutations in genes encoding nDRC proteins such as CCDC164, CCDC65 and GAS8 did not exhibit any situs abnormalities.

Given the large size of the regions sequenced in PCD patients, it is not unusual to identify one or several rare missense variants that are not linked to the disease. Great care should be taken to interpret those variants: it is important to perform segregation analysis for those variants and their interpretation can rely on expert labs. In some cases immunofluorescence microscopy (IF) has been proven to be a useful tool to determine pathogenicity of missense mutations in PCD individuals with mutations in RSPH4A and RSPH9 that encode radial spoke head proteins [94]. However, immunofluorescence analysis can be normal if the mutated protein is still expressed and correctly assembled within the axonemes such as reported for *DNAH11* missense mutations [71].

We did not find evidence to either confirm or refute genotyping as a diagnostic test for PCD. Whilst there is a need for evidence of the utility of genotyping in a diagnostic setting, Table 8 summarises the Task Force assessment of current published evidence in genetic testing in PCD.

*Key unanswered questions and research needs*

The role of genetic testing is not well defined in the PCD diagnostic pathway. We need studies to investigate the accuracy and limitations of genetics as a diagnostic tool for PCD. The standards for diagnostic testing for PCD need defining.

*Summary*

We were unable to determine the accuracy of genetics testing due to lack of suitable studies. Several studies have identified the genes responsible in patients with confirmed PCD, suggesting that genetic testing identifies the gene in approximately 65% of cases; this is likely to increase as more genes are identified. The question of diagnostic accuracy should be revisited as new data become available.

|  |
| --- |
| Task force statements on genetic testing for PCD |
| Whilst further evidence in a diagnostic setting is required, experts on the Task Force agreed:   1. Genetic testing to confirm diagnosis can be performed in PCD individuals diagnosed by other means (e.g. HSVA, TEM, IF) or in individuals with high clinical suspicion for PCD (typical clinical findings, low nasal NO) and no availability of other investigations such as HSVA, TEM or IF. A negative genetic test does not exclude PCD. 2. Genetic testing can also be performed to establish diagnosis in patients highly suspected of PCD and in whom HSVA, TEM or IF failed to confirm the diagnosis, as it can be the case for patients with *DNAH11*, *CCNO*, *MCIDAS* or *RSPH* gene mutations. 3. Genetic testing and interpretation of results should follow national and international best practice guidelines [115, 116]. 4. Genetic diagnosis has to be consistent with the clinical and TEM/IF/HSV phenotype, or diagnosis reconsidered if the picture is inconsistent. 5. Allelic segregation analysis within the family (especially in both parents) is important to confirm the genotype in the probands (to differentiate between homozygosity and hemizygosity, and between compound heterozygosity and a complex allele). 6. Genetic testing in probands and in their relatives is helpful for genetic counselling to inform reproductive choices. 7. In the future genetic testing might be important for genotype specific therapy. |

Table 8. Summary of the Task Force consensus on the published evidence on genetic testing in PCD diagnostics.

Immunofluorescence

In patients suspected of having PCD, should IF be used as a diagnostic tool?

There were no studies that fulfilled inclusion criteria to answer this question.

*Explanation of the diagnostic test*

Labelling of ciliary proteins was developed to improve understanding of the impact of disease-causing genes on ciliary proteins[117]. Specific antibodies with secondary fluorescent tags localise to proteins in human respiratory epithelial cells and are visualised by fluorescent or confocal microscopy. A number of antibodies against ciliary proteins are available including antibodies targeting the outer dynein arm, inner dynein arm, radial spoke head and dynein regulatory complex proteins. An example of this technique is shown in Figure 3.

Respiratory epithelial cells in suspension are placed onto glass slides, air-dried and fixed. The cells are incubated with antibodies to ciliary protein not implicated in PCD (e.g. acetylated tubulin) to label the axoneme, combined with antibodies of interest produced in a different species (e.g. anti-DNAH5 to identify outer dynein arm structures).

**Figure 3.** Representative immunofluorescence images of healthy controls and patients with GAS8, CCDC39 and RSPH9 mutations leading to absence of the protein in the cilia. Acetylated tubulin is used to stain the cilia and Hoechst 3342 to stain the nuclei. Scale bar is 10μm.

*Review of evidence directly addressing the question “in patients suspected of having PCD, should IF be used as a diagnostic tool?”*

Our search identified 276 studies (Supplementary Figure 1). No studies reported use of IF antibodies in a diagnostic setting and we were therefore unable to establish the accuracy of IF as a diagnostic test. Forty studies contributed to our understanding of the potential to use IF diagnostically, as summarized below (Supplementary Table 9).

*Narrative review of additional evidence*

Although the literature focuses on research to understand the downstream effects of mutations in PCD-related genes (Table 7), several centres now use IF to aid diagnosis[118]. This is likely to increase as more antibodies become available, and once data for the accuracy of the tests becomes available. In the two largest patient-based cohort studies, DNAH5 IF was tested in 16 PCD patients and a further 17 families who had ODA defects observed by TEM; mislocalisation of the protein was reported in all cases. Furthermore DNAH5 protein was present in patients with cystic fibrosis and in healthy controls [67, 69]. A number of studies have used IF to examine protein mislocalisation related to genetic mutations (Table 7), providing indicators to the antibodies that might be used and findings expected when IF is used as a diagnostic test. IF can identify mislocalisation of proteins in PCD patients with a range of mutations, providing information on the pathogenicity of a mutation [94]. However most manuscripts report IF findings from small numbers of patients for each gene and mutation specific findings are not yet known.

With IF it is possible to identify almost all ultrastructural abnormalities detectable by TEM and also some cases where the TEM is apparently normal or subtly abnormal [30, 71, 94]. The sensitivity and specificity of IF is unknown but will reflect the combination and quality of antibodies; in the authors’ experience, a number of antibodies do not work and validation including appropriate disease and healthy controls is required before they are used diagnostically. IF analysis can be normal if the mutated protein is still expressed within the axoneme [71].

We did not find evidence to either confirm or refute IF as a diagnostic test for PCD. Whilst further evidence in a diagnostic setting is required, the summary of Task Force findings from published evidence are shown in Table 9.

*Key unanswered questions and research needs*

We need validation studies to investigate the accuracy and limitations of IF as a diagnostic tool for PCD in diagnostic cohort studies. Each applied antibody needs validation in studies including appropriate PCD, disease and healthy controls.

*Summary*

We were unable to determine the accuracy of IF testing due to lack of suitable studies. Task force experts agree IF can be useful in clinical settings. IF is cheaper and easier than other diagnostic tests, providing a potential test for resource-limited settings.

|  |
| --- |
| Task force statements on IF testing for PCD |
| Whilst further evidence in a diagnostic setting is required, experts on the Task Force agreed:   1. IF is able to confirm pathogenesis of mutations (e.g. missense mutations in genes encoding radial spoke proteins). 2. IF can detect PCD in some cases with normal ultrastructure or subtle ultrastructural defects. 3. IF can help establish the diagnosis of PCD in ODA, IDA, tubular disorganisation (*CCDC39*/*CCDC40* mutations), central pair (genes encoding radial spoke proteins) and nexin link defects. |

Table 9. Summary of the Task Force consensus on the published evidence on immunofluorescence testing in PCD diagnostics.

Confirming or Excluding a Diagnosis of PCD

The Delphi Consensus Survey comprised four consecutive on-line surveys, each building on former rounds. The outcomes of each round are summarised in supplementary table 11. Experts from the ERS Task Force agreed (>80% of respondents) on the following, which enabled us to propose a diagnostic algorithm (Figure 4):

**Positive diagnosis:** For patients with a supportive history of PCD, the following results are confirmatory of a positive diagnosis of PCD:

* Hallmark ciliary ultrastructure defects for PCD (absence of outer dynein arms, combined absence of inner and outer dynein arms, inner dynein arm absence combined with microtubular disarrangement), assessed by TEM.
* Non-ambiguous biallelic mutations in PCD causing genes.

The task force did not reach consensus (80%) that any other test in isolation nor in combinations could provide a conclusive positive diagnosis.

**Highly likely diagnosis:** In patients with a compatible history of PCD the following diagnostic test results make the diagnosis of PCD highly likely, but do not provide a definitive PCD diagnosis.

* Very low nNO plus HSVA findings consistently suggestive of PCD (e.g. static cilia, circling) on three occasions.
* Very low nNO plus HSVA findings consistent with PCD (e.g. static cilia, circling) following cell culture.

If the diagnosis is ‘highly likely’ but not conclusive, patients should be told that the diagnosis is likely but given the limitations of diagnostic tests, the diagnosis is not 100% certain and might need confirmation when better tests become available. Patients should have other causes for their symptoms excluded and should be treated as if they have PCD. As new diagnostic tests become available further investigations should be offered.

**Excluding the diagnosis of PCD:** The Task Force did not reach consensus (80%) that any single test nor combination of tests could exclude a diagnosis of PCD. However, based on the evidence reviewed they agreed that there are conditions under which the diagnosis is ‘**extremely unlikely’**. If the clinical suspicion is only modest and:

* nNO is high/ normal plus normal HSVA, or
* nNO is high/ normal plus normal HSVA following cell culture,

the patient can be counselled that the diagnosis is extremely unlikely and that further testing is not warranted. If the clinical suspicion is very high (e.g. Kartagener’s syndrome, PICADAR score >10) current diagnostic tests are not sufficiently accurate to exclude a diagnosis.

**General statements:** Members of the Task Force suggest that diagnostic tests should only be conducted in laboratories with expertise in the field. The results should be interpreted by specialists with expertise in PCD and the results explained to the patient and their non-specialist carers. Diagnostic tests for PCD are currently imperfect. As our understanding and techniques for PCD advance, patients with a high clinical suspicion or inconclusive test results can be recalled and offered repeat testing.

A number of patients have diagnostic tests which do not satisfy the criteria for being labelled positive, ‘highly likely’ diagnosis or ‘extremely unlikely’. These patients should be considered inconclusive; further investigation and management should be determined by a specialist with expertise in PCD.

**Diagnostic Algorithm:** Based on the culmination of evidence from the GRADE recommendations and the Delphi Consensus statement, the following step-wise approach to diagnostic testing can be used (Figure 4). Not all patients need to undergo all steps. For many patients, step 1 (nNO and HSVM) will provide a ‘highly unlikely’ diagnosis, and patients won’t need further investigations. Some patients should proceed to step 2 (TEM or cell culture with repeat HSVM). Genetics testing (step 3) may help make a diagnosis in patients where other tests have failed to provide a definitive diagnostic outcome. Patients who remain ‘inconclusive’ could be recalled in the future as further tests become available. This approach will not be appropriate for all diagnostic services; local expertise and equipment should be taken into consideration.

**Step 1:** nNO  + HSVA

If both are entirely normal, the diagnosis of PCD is very unlikely and further testing can be avoided unless the clinical suspicion is particularly high.

If nNO is low and/ or HSVA is abnormal: PCD is the likely/ possible diagnosis- repeat these step 1 tests and proceed to step 2.

**Step 2**: TEM

If TEM is normal: consider genetics testing for genes associated with normal or subtle TEM defects and repeat HSVA following cell culture.

If TEM shows ‘hallmark’ defects PCD is confirmed: consider genetics testing to further characterise the underlying defect.

**Step 3:** Genetics and repeat HSVA +/- cell culture

**Further testing:** In patients where the diagnosis is highly likely or remains inconclusive, further investigations such as IF or radioaerosol mucociliary clearance analysis might be used but the evidence is too limited for us to recommend them. PCD clinicians should consider recalling these patients for further testing in the future, as advances in PCD diagnostics are made.

Discussion

The ERS Task Force presents the first evidence based guideline for the diagnosis of PCD. This is timely, as new diagnostic tests (e.g. ciliary protein immunofluorescence and genetic testing), are increasingly deployed along with refinement of existing tests (e.g. EM tomography and computational averaging). As new evidence arises, the guideline will need revisiting. We have provided guidance on who should be referred for diagnostic testing. We have confirmed that no diagnostic test is perfect, and in the absence of a gold standard, access to a combination of tests is necessary. Using a modified Delphi approach we then used the evidence for individual tests to develop a diagnostic algorithm, providing the criteria to define patients as positive, ‘highly unlikely ’extremely unlikely’ and inconclusive.

The studies that contribute to the recommendations were all conducted in specialist PCD diagnostic centres. The tests are generally complex, requiring experienced scientists and clinicians to analyses and interpret results. Our findings therefore provide evidence for diagnostic centres with high throughput of samples, analysed by experienced technicians and with good quality control. New diagnostic centres will require support from experienced centres for training and ongoing quality control/ assessment. BEATPCD (http://www.beatpcd.org/ COST ACTION BM 1407) is coordinating a programme of research and training to improve the diagnosis and treatment of PCD. This includes provision of training schools, bursaries for short-term placements in specialist centres and networking for discussion of difficult and equivocal diagnostic decisions. Together with the anticipated European Reference Network for PCD, the collaborative approach should drive up standards of diagnostic testing across Europe.

Results from diagnostic studies are an indirect measure of the downstream consequences of the application of a test, and therefore the confidence in the test accuracy measures was judged at best moderate to low. Evidence from patients does not alter the strength of published evidence but was considered when deciding the strength of recommendations. The Task Force conducted a questionnaire survey of 352 PCD patients from 25 countries, and 20 in-depth interviews [7]. Patients told us that an accurate diagnosis was an important outcome, leading to a better recognition of their problems by physicians and access to effective treatment, thus improving their health and quality of life.

Once the Task Force recommendations were agreed, a modified-Delphi survey was used to develop a consensus on diagnostic approach. Experts from the Task Force agreed that results from TEM and genetic testing can lead to a definite positive diagnosis. This provides a guide for future clinical trials as well as clinical care, with the caution that our definition will systematically exclude PCD patients with normal ciliary ultrastructure where the genetic mutations are not yet known. Furthermore, most of the Task Force (>50%) considered that the following combinations of tests could lead to a positive diagnosis, but we did not reach consensus (defined by >80%): Very low nNO PLUS hallmark HSVM consistently on two occasions; very low nNO PLUS hallmark HSVM following cell culture (supplementary table 11). We have also defined conditions where the diagnosis of PCD can be considered as ‘extremely likely’ and where diagnosis is ‘extremely unlikely’. Given the current evidence, it is not possible to exclude a diagnosis with 100% confidence, but we have defined situations where further testing can reasonably stop. We anticipate that as our understanding of PCD grows, new phenotypes for this highly heterogeneous condition will be described that might not be detected by current diagnostic tests.

All studies that contribute to our recommendations were hampered by the lack of a gold standard to investigate the accuracy of individual tests. We therefore accepted manuscripts that constructed a reference standard from a number of tests (‘composite diagnostic outcome’) or used an imperfect test e.g. TEM as a surrogate [119]. Studies using TEM or genetics as the reference standard will systematically exclude PCD patients with normal ultrastructure or where the genetic mutation is not known. Additionally, some of the evidence was based on studies where the index test was included in the composite diagnostic decision. These important limitations present a strong risk of bias and may have over inflated or deflated the sensitivity and specificity that we report for each test. None of the diagnostic tests had internationally agreed standards for conduct or reporting. This resulted in disparity of methods between the studies that we reviewed. The Task Force suggests that the following need to be taken into consideration to advance our understanding of diagnostic tests for PCD:

1. Methodologists should be involved in the design of future studies to investigate diagnostic accuracy of tests. Consideration is needed for the lack of a perfect reference standard.
2. To allow comparisons between studies, international standards for conduct of diagnostic tests and reporting of results is needed. The standards should be evidence based.
3. Reporting of the clinical phenotype of patients included in diagnostic studies should be improved and standardized.
4. Impact of a diagnosis on patient outcome and quality of life should be investigated.

References

1. Lucas JS, Leigh MW. Diagnosis of primary ciliary dyskinesia: searching for a gold standard. *Eur. Respir. J.* 2014; 44: 1418–1422.

2. Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G, Bartoloni L, Eber E, Escribano A, Haarman E, Hesselmar B, Hogg C, Jorissen M, Lucas J, Nielsen KG, O’Callaghan C, Omran H, Pohunek P, Strippoli M-PF, Bush A. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. *Eur. Respir. J.* 2009; 34: 1264–1276.

3. Kuehni CE, Frischer T, Strippoli M-PF, Maurer E, Bush A, Nielsen KG, Escribano A, Lucas JSA, Yiallouros P, Omran H, Eber E, O’Callaghan C, Snijders D, Barbato A. Factors influencing age at diagnosis of primary ciliary dyskinesia in European children. *Eur. Respir. J.* 2010; 36: 1248–1258.

4. Strippoli M-PF, Frischer T, Barbato A, Snijders D, Maurer E, Lucas JSA, Eber E, Karadag B, Pohunek P, Zivkovic Z, Escribano A, O’Callaghan C, Bush A, Kuehni CE. Management of primary ciliary dyskinesia in European children: recommendations and clinical practice. *Eur. Respir. J.* 2012; 39: 1482–1491.

5. Schünemann HJ, Schünemann AHJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, Williams JW, Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ* 2008; 336: 1106–1110.

6. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schünemann HJ. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J. Clin. Epidemiol.* 2011; 64: 395–400.

7. Behan L, Dunn G, Rubbo B, Masefield S, Copeland F, Manion M, Rindlisbacher B, Redfern B, Lucas JSA. Diagnosing primary ciliary dyskinesia; an international patient perspective. Eur Respir J 2016; in press DOI: 10.1183/13993003.02018-2015

8. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE guidelines: 3. Rating the quality of evidence. *J. Clin. Epidemiol.* 2011; 64: 401–406.

9. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, Montori VM, Brito JP, Norris S, Elbarbary M, Post P, Nasser M, Shukla V, Jaeschke R, Brozek J, Djulbegovic B, Guyatt G. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. *J. Clin. Epidemiol.* 2013; 66: 726–735.

10. Behan L, Dimitrov BD, Kuehni CE, Hogg C, Carroll M, Evans HJ, Goutaki M, Harris A, Packham S, Walker WT, Lucas JS. PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia. *Eur. Respir. J.* 2016; 47: 1103–1112.

11. Shapiro AJ, Chawla KK, Baker BR, Minnix S, Davis SD, Knowles MR, Leigh MW. Nasal nitric oxide and clinical characteristics of patients with heterotaxy: Comparison to primary ciliary dyskinesia. Am. J. Respir. Crit. Care Med. American Thoracic Society; 2011.

12. Leigh MW, Ferkol TW, Davis SD, Lee H-S, Rosenfeld M, Dell SD, Sagel SD, Milla C, Olivier KN, Sullivan KM, Zariwala MA, Pittman J, Shapiro AJ, Carson JL, Krischer J, Hazucha MJ, Knowles MR. Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. *Ann. Am. Thorac. Soc.* 2016; .

13. Noll EM, Rieger CHL, Hamelmann E, Nüsslein TG. Questionnaire to preselect patients with a high probability of primary ciliary dyskinesia. *Klin. Pädiatrie* 2011; 223: 22–26.

14. Beucher J, Chambellan A, Segalen J, Deneuville E. [Primary ciliary dyskinesia: a retrospective review of clinical and paraclinical data]. *Rev. Mal. Respir.* 2011; 28: 856–863.

15. Pifferi M, Bush A, Michelucci A, Di Cicco M, Piras M, Caramella D, Mazzei F, Neri M, Pioggia G, Tartarisco G, Saggese G, Simi P, Boner AL. Mannose-binding lectin 2 gene polymorphism and lung damage in primary ciliary dyskinesia. *Pediatr. Pulmonol.* 2015; 50: 179–186.

16. Mullowney T, Manson D, Kim R, Stephens D, Shah V, Dell S. Primary ciliary dyskinesia and neonatal respiratory distress. *Pediatrics* 2014; 134: 1160–1166.

17. Goutaki M, Meier A, Halbeisen FS, Lucas JSA, Dell SD, Maurer E, Casaulta C, Jurca M, Spycher BD, Kuehni CE. Clinical manifestations in Primary Ciliary Dyskinesia: a systematic review and metaanalysis. Eur Respir J 2016; in press.

18. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. *Eur. Heart J.* 2014; 35: 1925–1931.

19. Walker WT, Jackson CL, Lackie PM, Hogg C, Lucas JS. Nitric oxide in primary ciliary dyskinesia. *Eur. Respir. J.* 2012; 40: 1024–1032.

20. Collins SA, Gove K, Walker W, Lucas JSA. Nasal nitric oxide screening for primary ciliary dyskinesia: systematic review and meta-analysis. *Eur. Respir. J.* 2014; 44: 1589–1599.

21. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am. J. Respir. Crit. Care Med.* 2005; 171: 912–930.

22. Beydon N, Chambellan A, Alberti C, de Blic J, Clément A, Escudier E, Le Bourgeois M. Technical and practical issues for tidal breathing measurements of nasal nitric oxide in children. *Pediatr. Pulmonol.* 2015; 50: 1374–1382.

23. Marthin JK, Nielsen KG. Hand-held tidal breathing nasal nitric oxide measurement--a promising targeted case-finding tool for the diagnosis of primary ciliary dyskinesia. *PLoS One* 2013; 8: e57262.

24. Marthin JK, Nielsen KG. Choice of nasal nitric oxide technique as first-line test for primary ciliary dyskinesia. *Eur. Respir. J.* 2011; 37: 559–565.

25. Leigh MW, Hazucha MJ, Chawla KK, Baker BR, Shapiro AJ, Brown DE, Lavange LM, Horton BJ, Qaqish B, Carson JL, Davis SD, Dell SD, Ferkol TW, Atkinson JJ, Olivier KN, Sagel SD, Rosenfeld M, Milla C, Lee H-S, Krischer J, Zariwala MA, Knowles MR. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. *Ann. Am. Thorac. Soc.* 2013; 10: 574–581.

26. Jackson CL, Behan L, Collins SA, Goggin PM, Adam EC, Coles JL, Evans HJ, Harris A, Lackie P, Packham S, Page A, Thompson J, Walker WT, Kuehni C, Lucas JS. Accuracy of diagnostic testing in primary ciliary dyskinesia. *Eur. Respir. J.* 2015; In Press: ERJ – 00749–02015.

27. Harris A, Bhullar E, Gove K, Joslin R, Pelling J, Evans HJ, Walker WT, Lucas JS. Validation of a portable nitric oxide analyzer for screening in primary ciliary dyskinesias. *BMC Pulm. Med.* 2014; 14: 18.

28. Struben VMD, Wieringa MH, Mantingh CJ, Bommeljé C, Don M, Feenstra L, de Jongste JC. Nasal NO: normal values in children age 6 through to 17 years. *Eur. Respir. J.* 2005; 26: 453–457.

29. Adams PS, Tian X, Zahid M, Khalifa O, Leatherbury L, Lo CW. Establishing normative nasal nitric oxide values in infants. *Respir. Med.* 2015; 109: 1126–1130.

30. Olbrich H, Cremers C, Loges NT, Werner C, Nielsen KG, Marthin JK, Philipsen M, Wallmeier J, Pennekamp P, Menchen T, Edelbusch C, Dougherty GW, Schwartz O, Thiele H, Altmüller J, Rommelmann F, Omran H. Loss-of-Function GAS8 Mutations Cause Primary Ciliary Dyskinesia and Disrupt the Nexin-Dynein Regulatory Complex. *Am. J. Hum. Genet.* 2015; 97: 546–554.

31. Knowles MR, Ostrowski LE, Leigh MW, Sears PR, Davis SD, Wolf WE, Hazucha MJ, Carson JL, Olivier KN, Sagel SD, Rosenfeld M, Ferkol TW, Dell SD, Milla CE, Randell SH, Yin W, Sannuti A, Metjian HM, Noone PJPG, Noone PJPG, Olson CA, Patrone M V, Dang H, Lee H-S, Hurd TW, Gee HY, Otto EA, Halbritter J, Kohl S, Kircher M, et al. Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype. *Am. J. Respir. Crit. Care Med.* 2014; 189: 707–717.

32. Kott E, Legendre M, Copin B, Papon J-F, Dastot-Le Moal F, Montantin G, Duquesnoy P, Piterboth W, Amram D, Bassinet L, Beucher J, Beydon N, Deneuville E, Houdouin V, Journel H, Just J, Nathan N, Tamalet A, Collot N, Jeanson L, Le Gouez M, Vallette B, Vojtek A-M, Epaud R, Coste A, Clement A, Housset B, Louis B, Escudier E, Amselem S. Loss-of-function mutations in RSPH1 cause primary ciliary dyskinesia with central-complex and radial-spoke defects. *Am. J. Hum. Genet.* 2013; 93: 561–570.

33. Afzelius BA. A human syndrome caused by immotile cilia. *Science* 1976; 193: 317–319.

34. Rayner CF, Rutman A, Dewar A, Greenstone MA, Cole PJ, Wilson R. Ciliary disorientation alone as a cause of primary ciliary dyskinesia syndrome. *Am. J. Respir. Crit. Care Med.* 1996; 153: 1123–1129.

35. Chapelin C, Coste A, Reinert P, Boucherat M, Millepied MC, Poron F, Escudier E. Incidence of primary ciliary dyskinesia in children with recurrent respiratory diseases. *Ann. Otol. Rhinol. Laryngol.* 1997; 106: 854–858.

36. Santamaria, MM de Santi, G Grillo, F. Ciliary motility at light microscopy: a screening technique for ciliary defects? *Acta Paediatr.* 1999; 88: 853–857.

37. Jorissen M, Willems T, Van der Schueren B, Verbeken E, De Boeck K. Ultrastructural expression of primary ciliary dyskinesia after ciliogenesis in culture. *Acta Otorhinolaryngol. Belg.* 2000; 54: 343–356.

38. Toskala-Hannikainen E, Haataja J, Shirasaki H, Rautiainen M. Culture of cells harvested with nasal brushing: A method for evaluating ciliary function. *Rhinology* 2005; 43: 121–124.

39. Pifferi M, Montemurro F, Cangiotti AM, Ragazzo V, Di Cicco M, Vinci B, Vozzi G, Macchia P, Boner AL. Simplified cell culture method for the diagnosis of atypical primary ciliary dyskinesia. *Thorax* 2009; 64: 1077–1081.

40. Hirst RA, Jackson CL, Coles JL, Williams G, Rutman A, Goggin PM, Adam EC, Page A, Evans HJ, Lackie PM, O’Callaghan C, Lucas JS. Culture of Primary Ciliary Dyskinesia Epithelial Cells at Air-Liquid Interface Can Alter Ciliary Phenotype but Remains a Robust and Informative Diagnostic Aid. *PLoS One* 2014; 9: e89675.

41. Chilvers M a, O’Callaghan C. Analysis of ciliary beat pattern and beat frequency using digital high speed imaging: comparison with the photomultiplier and photodiode methods. *Thorax* 2000; 55: 314–317.

42. Papon J-F, Bassinet L, Cariou-Patron G, Zerah-Lancner F, Vojtek A-M, Blanchon S, Crestani B, Amselem S, Coste A, Housset B, Escudier E, Louis B. Quantitative analysis of ciliary beating in primary ciliary dyskinesia: a pilot study. *Orphanet J. Rare Dis.* 2012; 7: 78.

43. Friedman NR, Pachigolla R, Deskin RW, Hawkins HK. Optimal Technique to Diagnose Primary Ciliary Dyskinesia. *Laryngoscope* 2000; 110: 1548–1551.

44. Chilvers MA, Rutman A, O’Callaghan C. Ciliary beat pattern is associated with specific ultrastructural defects in primary ciliary dyskinesia. *J. Allergy Clin. Immunol.* 2003; 112: 518–524.

45. Raidt J, Wallmeier J, Grose Onnebrink J, Pennekamp P, Loges NT, Olbrich H, Dougherty G, Omran H, Werner C. Identification of distinct ciliary beat pattern abnormalities by high-speed video microscopy in primary ciliary dyskinesia. *Pediatr. Pulmonol.* 2014; 49: S48.

46. Pifferi M, Bush A, Montemurro F, Pioggia G, Piras M, Tartarisco G, Di Cicco M, Chinellato I, Cangiotti AM, Boner AL. Rapid diagnosis of primary ciliary dyskinesia: cell culture and soft computing analysis. *Eur. Respir. J.* 2013; 41: 960–965.

47. Jorissen M, Willems T, Van der Schueren B. Ciliary function analysis for the diagnosis of primary ciliary dyskinesia: advantages of ciliogenesis in culture. *Acta Otolaryngol.* 2000; 120: 291–295.

48. Stannard WA, Chilvers MA, Rutman AR, Williams CD, O’Callaghan C. Diagnostic Testing of Patients Suspected of Primary Ciliary Dyskinesia. *Am. J. Respir. Crit. Care Med.* 2010; 181: 307–314.

49. Raidt J, Wallmeier J, Hjeij R, Onnebrink JG, Pennekamp P, Loges NT, Olbrich H, Häffner K, Dougherty GW, Omran H, Werner C. Ciliary beat pattern and frequency in genetic variants of primary ciliary dyskinesia. *Eur. Respir. J.* 2014; 44: 1579–1588.

50. Schwabe GC, Hoffmann K, Loges NT, Birker D, Rossier C, de Santi MM, Olbrich H, Fliegauf M, Failly M, Liebers U, Collura M, Gaedicke G, Mundlos S, Wahn U, Blouin J-L, Niggemann B, Omran H, Antonarakis SE, Bartoloni L. Primary ciliary dyskinesia associated with normal axoneme ultrastructure is caused by DNAH11 mutations. *Hum. Mutat.* 2008; 29: 289–298.

51. Sturgess JM, Turner JA. Ultrastructural pathology of cilia in the immotile cilia syndrome. *Perspect. Pediatr. Pathol.* 1984; 8: 133–161.

52. Rutland J, Dewar A, Cox T, Cole P. Nasal brushing for the study of ciliary ultrastructure. *J. Clin. Pathol.* 1982; 35: 357–359.

53. Munkholm M, Nielsen KG, Mortensen J. Clinical value of measurement of pulmonary radioaerosol mucociliary clearance in the work up of primary ciliary dyskinesia. *EJNMMI Res.* 2015; 5: 118.

54. Pifferi M, Caramella D, Cangiotti AM, Ragazzo V, Macchia P, Boner AL. Nasal Nitric Oxide in Atypical Primary Ciliary Dyskinesia. *Chest* 2007; 131: 870–873.

55. Hirst RA, Rutman A, Williams G, O’Callaghan C. Ciliated Air-Liquid Cultures as an Aid to Diagnostic Testing of Primary Ciliary Dyskinesia. *Chest* 2010; 138: 1441–1447.

56. Papon JF, Coste A, Roudot-Thoraval F, Boucherat M, Roger G, Tamalet A, Vojtek AM, Amselem S, Escudier E. A 20-year experience of electron microscopy in the diagnosis of primary ciliary dyskinesia. *Eur. Respir. J.* 2010; 35: 1057–1063.

57. Olm MAK, Kögler JE, Macchione M, Shoemark A, Saldiva PHN, Rodrigues JC. Primary ciliary dyskinesia: evaluation using cilia beat frequency assessment via spectral analysis of digital microscopy images. *J. Appl. Physiol.* 2011; 111: 295–302.

58. Shoemark A, Dixon M, Corrin B, Dewar A. Twenty-year review of quantitative transmission electron microscopy for the diagnosis of primary ciliary dyskinesia. *J. Clin. Pathol.* England; 2012; 65: 267–271.

59. Olin JT, Burns K, Carson JL, Metjian H, Atkinson JJ, Davis SD, Dell SD, Ferkol TW, Milla CE, Olivier KN, Rosenfeld M, Baker B, Leigh MW, Knowles MR, Sagel SD. Diagnostic yield of nasal scrape biopsies in primary ciliary dyskinesia: a multicenter experience. *Pediatr. Pulmonol.* 2011; 46: 483–488.

60. Boon M, Smits A, Cuppens H, Jaspers M, Proesmans M, Dupont LJ, Vermeulen FL, Van Daele S, Malfroot A, Godding V, Jorissen M, De Boeck K. Primary ciliary dyskinesia: critical evaluation of clinical symptoms and diagnosis in patients with normal and abnormal ultrastructure. *Orphanet J. Rare Dis.* England; 2014; 9: 11.

61. Escudier E, Couprie M, Duriez B, Roudot-Thoraval F, Millepied M-C, Prulière-Escabasse V, Labatte L, Coste A. Computer-assisted analysis helps detect inner dynein arm abnormalities. *Am. J. Respir. Crit. Care Med.* 2002; 166: 1257–1262.

62. Funkhouser WK, Niethammer M, Carson JL, Burns KA, Knowles MR, Leigh MW, Zariwala MA, Funkhouser WK. A new tool improves diagnostic test performance for transmission em evaluation of axonemal dynein arms. *Ultrastruct. Pathol.* 2014; 38: 248–255.

63. Smith CM, Hirst RA, Bankart MJ, Jones DW, Easton AJ, Andrew PW, O’Callaghan C. Cooling of Cilia Allows Functional Analysis of the Beat Pattern for Diagnostic Testing. *Chest* 2011; 140: 186–190.

64. Shoemark A, Hogg C. Electron tomography of respiratory cilia. *Thorax* 2013; 68: 190–191.

65. Wallmeier J, Al-Mutairi DA, Chen C-T, Loges NT, Pennekamp P, Menchen T, Ma L, Shamseldin HE, Olbrich H, Dougherty GW, Werner C, Alsabah BH, Köhler G, Jaspers M, Boon M, Griese M, Schmitt-Grohé S, Zimmermann T, Koerner-Rettberg C, Horak E, Kintner C, Alkuraya FS, Omran H. Mutations in CCNO result in congenital mucociliary clearance disorder with reduced generation of multiple motile cilia. *Nat. Genet.* 2014; 46: 646–651.

66. Olbrich H, Häffner K, Kispert A, Völkel A, Volz A, Sasmaz G, Reinhardt R, Hennig S, Lehrach H, Konietzko N, Zariwala M, Noone PG, Knowles M, Mitchison HM, Meeks M, Chung EMK, Hildebrandt F, Sudbrak R, Omran H. Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left-right asymmetry. *Nat. Genet.* Nature Publishing Group; 2002; 30: 143–144.

67. Fliegauf M, Olbrich H, Horvath J, Wildhaber JH, Zariwala MA, Kennedy M, Knowles MR, Omran H. Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia. *Am. J. Respir. Crit. Care Med.* 2005; 171: 1343–1349.

68. Loges NT, Olbrich H, Fenske L, Mussaffi H, Horvath J, Fliegauf M, Kuhl H, Baktai G, Peterffy E, Chodhari R, Chung EMK, Rutman A, O’Callaghan C, Blau H, Tiszlavicz L, Voelkel K, Witt M, Ziętkiewicz E, Neesen J, Reinhardt R, Mitchison HM, Omran H. DNAI2 Mutations Cause Primary Ciliary Dyskinesia with Defects in the Outer Dynein Arm. *Am. J. Hum. Genet.* 2008; 83: 547–558.

69. Hornef N, Olbrich H, Horvath J, Zariwala MA, Fliegauf M, Loges NT, Wildhaber J, Noone PG, Kennedy M, Antonarakis SE, Blouin J-L, Bartoloni L, Nüsslein T, Ahrens P, Griese M, Kuhl H, Sudbrak R, Knowles MR, Reinhardt R, Omran H. DNAH5 mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects. *Am. J. Respir. Crit. Care Med.* 2006; 174: 120–126.

70. Knowles MR, Leigh MW, Carson JL, Davis SD, Dell SD, Ferkol TW, Olivier KN, Sagel SD, Rosenfeld M, Burns KA, Minnix SL, Armstrong MC, Lori A, Hazucha MJ, Loges NT, Olbrich H, Becker-Heck A, Schmidts M, Werner C, Omran H, Zariwala MA. Mutations of DNAH11 in patients with primary ciliary dyskinesia with normal ciliary ultrastructure. *Thorax* 2012; 67: 433–441.

71. Dougherty GW, Loges NT, Klinkenbusch JA, Olbrich H, Pennekamp P, Menchen T, Raidt J, Wallmeier J, Werner C, Westermann C, Ruckert C, Mirra V, Hjeij R, Memari Y, Durbin R, Kolb-Kokocinski A, Praveen K, Kashef MA, Kashef S, Eghtedari F, Häffner K, Valmari P, Baktai G, Aviram M, Bentur L, Amirav I, Davis EE, Katsanis N, Brueckner M, Shaposhnykov A, et al. DNAH11 Localization in the Proximal Region of Respiratory Cilia Defines Distinct Outer Dynein Arm Complexes. *Am. J. Respir. Cell Mol. Biol.* 2016; .

72. Pennarun G, Escudier E, Chapelin C, Bridoux AM, Cacheux V, Roger G, Clément A, Goossens M, Amselem S, Duriez B. Loss-of-function mutations in a human gene related to Chlamydomonas reinhardtii dynein IC78 result in primary ciliary dyskinesia. *Am. J. Hum. Genet.* 1999; 65: 1508–1519.

73. Duriez B, Duquesnoy P, Escudier E, Bridoux A-M, Escalier D, Rayet I, Marcos E, Vojtek A-M, Bercher J-F, Amselem S. A common variant in combination with a nonsense mutation in a member of the thioredoxin family causes primary ciliary dyskinesia. *Proc. Natl. Acad. Sci. U. S. A.* 2007; 104: 3336–3341.

74. Mazor M, Alkrinawi S, Chalifa-Caspi V, Manor E, Sheffield VC, Aviram M, Parvari R. Primary ciliary dyskinesia caused by homozygous mutation in DNAL1, encoding dynein light chain 1. *Am. J. Hum. Genet.* 2011; 88: 599–607.

75. Hjeij R, Onoufriadis A, Watson CM, Slagle CE, Klena NT, Dougherty GW, Kurkowiak M, Loges NT, Diggle CP, Morante NFC, Gabriel GC, Lemke KL, Li Y, Pennekamp P, Menchen T, Konert F, Marthin JK, Mans DA, Letteboer SJF, Werner C, Burgoyne T, Westermann C, Rutman A, Carr IM, O’Callaghan C, Moya E, Chung EMK, Sheridan E, Nielsen KG, Roepman R, et al. CCDC151 mutations cause primary ciliary dyskinesia by disruption of the outer dynein arm docking complex formation. *Am. J. Hum. Genet.* 2014; 95: 257–274.

76. Onoufriadis A, Paff T, Antony D, Shoemark A, Micha D, Kuyt B, Schmidts M, Petridi S, Dankert-Roelse JE, Haarman EG, Daniels JMA, Emes RD, Wilson R, Hogg C, Scambler PJ, Chung EMK, Pals G, Mitchison HM. Splice-site mutations in the axonemal outer dynein arm docking complex gene CCDC114 cause primary ciliary dyskinesia. *Am. J. Hum. Genet.* 2013; 92: 88–98.

77. Onoufriadis A, Shoemark A, Munye MM, James CT, Schmidts M, Patel M, Rosser EM, Bacchelli C, Beales PL, Scambler PJ, Hart SL, Danke-Roelse JE, Sloper JJ, Hull S, Hogg C, Emes RD, Pals G, Moore AT, Chung EMK, Mitchison HM. Combined exome and whole-genome sequencing identifies mutations in ARMC4 as a cause of primary ciliary dyskinesia with defects in the outer dynein arm. *J. Med. Genet.* 2014; 51: 61–67.

78. Hjeij R, Lindstrand A, Francis R, Zariwala MA, Liu X, Li Y, Damerla R, Dougherty GW, Abouhamed M, Olbrich H, Loges NT, Pennekamp P, Davis EE, Carvalho CMB, Pehlivan D, Werner C, Raidt J, Köhler G, Häffner K, Reyes-Mugica M, Lupski JR, Leigh MW, Rosenfeld M, Morgan LC, Knowles MR, Lo CW, Katsanis N, Omran H. ARMC4 mutations cause primary ciliary dyskinesia with randomization of left/right body asymmetry. *Am. J. Hum. Genet.* 2013; 93: 357–367.

79. Panizzi JR, Becker-Heck A, Castleman VH, Al-Mutairi DA, Liu Y, Loges NT, Pathak N, Austin-Tse C, Sheridan E, Schmidts M, Olbrich H, Werner C, Häffner K, Hellman N, Chodhari R, Gupta A, Kramer-Zucker A, Olale F, Burdine RD, Schier AF, O’Callaghan C, Chung EMK, Reinhardt R, Mitchison HM, King SM, Omran H, Drummond IA. CCDC103 mutations cause primary ciliary dyskinesia by disrupting assembly of ciliary dynein arms. *Nat. Genet.* 2012; 44: 714–719.

80. Tarkar A, Loges NT, Slagle CE, Francis R, Dougherty GW, Tamayo J V, Shook B, Cantino M, Schwartz D, Jahnke C, Olbrich H, Werner C, Raidt J, Pennekamp P, Abouhamed M, Hjeij R, Köhler G, Griese M, Li Y, Lemke K, Klena N, Liu X, Gabriel G, Tobita K, Jaspers M, Morgan LC, Shapiro AJ, Letteboer SJF, Mans DA, Carson JL, et al. DYX1C1 is required for axonemal dynein assembly and ciliary motility. *Nat. Genet.* 2013; 45: 995–1003.

81. Knowles MR, Ostrowski LE, Loges NT, Hurd T, Leigh MW, Huang L, Wolf WE, Carson JL, Hazucha MJ, Yin W, Davis SD, Dell SD, Ferkol TW, Sagel SD, Olivier KN, Jahnke C, Olbrich H, Werner C, Raidt J, Wallmeier J, Pennekamp P, Dougherty GW, Hjeij R, Gee HY, Otto EA, Halbritter J, Chaki M, Diaz KA, Braun DA, Porath JD, et al. Mutations in SPAG1 cause primary ciliary dyskinesia associated with defective outer and inner dynein arms. *Am. J. Hum. Genet.* 2013; 93: 711–720.

82. Horani A, Ferkol, Shoseyov D, Wasserman, Oren YS, Kerem B, Amirav I, Cohen-Cymberknoh M, Dutcher SK, Brody SL, Elpeleg O, Kerem E. LRRC6 Mutation Causes Primary Ciliary Dyskinesia with Dynein Arm Defects. *PLoS One* 2013; 8: e59436.

83. Kott E, Duquesnoy P, Copin B, Legendre M, Dastot-Le Moal F, Montantin G, Jeanson L, Tamalet A, Papon J-F, Siffroi J-P, Rives N, Mitchell V, de Blic J, Coste A, Clement A, Escalier D, Touré A, Escudier E, Amselem S. Loss-of-function mutations in LRRC6, a gene essential for proper axonemal assembly of inner and outer dynein arms, cause primary ciliary dyskinesia. *Am. J. Hum. Genet.* 2012; 91: 958–964.

84. Zariwala MA, Gee HY, Kurkowiak M, Al-Mutairi DA, Leigh MW, Hurd TW, Hjeij R, Dell SD, Chaki M, Dougherty GW, Adan M, Spear PC, Esteve-Rudd J, Loges NT, Rosenfeld M, Diaz KA, Olbrich H, Wolf WE, Sheridan E, Batten TFC, Halbritter J, Porath JD, Kohl S, Lovric S, Hwang D-Y, Pittman JE, Burns KA, Ferkol TW, Sagel SD, Olivier KN, et al. ZMYND10 is mutated in primary ciliary dyskinesia and interacts with LRRC6. *Am. J. Hum. Genet.* 2013; 93: 336–345.

85. Omran H, Kobayashi D, Olbrich H, Tsukahara T, Loges NT, Hagiwara H, Zhang Q, Leblond G, O’Toole E, Hara C, Mizuno H, Kawano H, Fliegauf M, Yagi T, Koshida S, Miyawaki A, Zentgraf H, Seithe H, Reinhardt R, Watanabe Y, Kamiya R, Mitchell DR, Takeda H. Ktu/PF13 is required for cytoplasmic pre-assembly of axonemal dyneins. *Nature* 2008; 456: 611–616.

86. Duquesnoy P, Escudier E, Vincensini L, Freshour J, Bridoux A-M, Coste A, Deschildre A, de Blic J, Legendre M, Montantin G, Tenreiro H, Vojtek A-M, Loussert C, Clément A, Escalier D, Bastin P, Mitchell DR, Amselem S. Loss-of-Function Mutations in the Human Ortholog of Chlamydomonas reinhardtii ODA7 Disrupt Dynein Arm Assembly and Cause Primary Ciliary Dyskinesia. *Am. J. Hum. Genet.* 2009; 85: 890–896.

87. Loges NT, Olbrich H, Becker-Heck A, Häffner K, Heer A, Reinhard C, Schmidts M, Kispert A, Zariwala MA, Leigh MW, Knowles MR, Zentgraf H, Seithe H, Nürnberg G, Nürnberg P, Reinhardt R, Omran H. Deletions and Point Mutations of LRRC50 Cause Primary Ciliary Dyskinesia Due to Dynein Arm Defects. *Am. J. Hum. Genet.* 2009; 85: 883–889.

88. Austin-Tse C, Halbritter J, Zariwala MA, Gilberti RM, Gee HY, Hellman N, Pathak N, Liu Y, Panizzi JR, Patel-King RS, Tritschler D, Bower R, O’Toole E, Porath JD, Hurd TW, Chaki M, Diaz KA, Kohl S, Lovric S, Hwang D-Y, Braun DA, Schueler M, Airik R, Otto EA, Leigh MW, Noone PG, Carson JL, Davis SD, Pittman JE, Ferkol TW, et al. Zebrafish ciliopathy screen plus human mutational analysis identifies C21orf59 and CCDC65 defects as causing primary ciliary dyskinesia. *Am. J. Hum. Genet.* 2013; 93: 672–686.

89. Mitchison HM, Schmidts M, Loges NT, Freshour J, Dritsoula A, Hirst RA, O’Callaghan C, Blau H, Al Dabbagh M, Olbrich H, Beales PL, Yagi T, Mussaffi H, Chung EMK, Omran H, Mitchell DR. Mutations in axonemal dynein assembly factor DNAAF3 cause primary ciliary dyskinesia. *Nat. Genet.* 2012; 44: 381–389, S1–S2.

90. Kurkowiak M, Ziętkiewicz E, Greber A, Voelkel K, Wojda A, Pogorzelski A, Witt M. ZMYND10 - Mutation Analysis in Slavic Patients with Primary Ciliary Dyskinesia. *PLoS One* 2016; 11: e0148067.

91. Horani A, Druley TE, Zariwala MA, Patel AC, Levinson BT, Van Arendonk LG, Thornton KC, Giacalone JC, Albee AJ, Wilson KS, Turner EH, Nickerson DA, Shendure J, Bayly P V, Leigh MW, Knowles MR, Brody SL, Dutcher SK, Ferkol TW. Whole-exome capture and sequencing identifies HEATR2 mutation as a cause of primary ciliary dyskinesia. *Am. J. Hum. Genet.* 2012; 91: 685–693.

92. Diggle CP, Moore DJ, Mali G, zur Lage P, Ait-Lounis A, Schmidts M, Shoemark A, Garcia Munoz A, Halachev MR, Gautier P, Yeyati PL, Bonthron DT, Carr IM, Hayward B, Markham AF, Hope JE, von Kriegsheim A, Mitchison HM, Jackson IJ, Durand B, Reith W, Sheridan E, Jarman AP, Mill P. HEATR2 plays a conserved role in assembly of the ciliary motile apparatus. *PLoS Genet.* 2014; 10: e1004577.

93. Olbrich H, Schmidts M, Werner C, Onoufriadis A, Loges NT, Raidt J, Banki NF, Shoemark A, Burgoyne T, Al Turki S, Hurles ME, Köhler G, Schroeder J, Nürnberg G, Nürnberg P, Chung EMK, Reinhardt R, Marthin JK, Nielsen KG, Mitchison HM, Omran H. Recessive HYDIN mutations cause primary ciliary dyskinesia without randomization of left-right body asymmetry. *Am. J. Hum. Genet.* 2012; 91: 672–684.

94. Frommer A, Hjeij R, Loges NT, Edelbusch C, Jahnke C, Raidt J, Werner C, Wallmeier J, Große-Onnebrink J, Olbrich H, Cindrić S, Jaspers M, Boon M, Memari Y, Durbin R, Kolb-Kokocinski A, Sauer S, Marthin JK, Nielsen KG, Amirav I, Elias N, Kerem E, Shoseyov D, Haeffner K, Omran H. Immunofluorescence Analysis and Diagnosis of Primary Ciliary Dyskinesia with Radial Spoke Defects. *Am. J. Respir. Cell Mol. Biol.* 2015; 53: 563–573.

95. Onoufriadis A, Shoemark A, Schmidts M, Patel M, Jimenez G, Liu H, Thomas B, Dixon M, Hirst RA, Rutman A, Burgoyne T, Williams C, Scully J, Bolard F, Lafitte J-J, Beales PL, Hogg C, Yang P, Chung EMK, Emes RD, O’Callaghan C, Bouvagnet P, Mitchison HM. Targeted NGS gene panel identifies mutations in RSPH1 causing primary ciliary dyskinesia and a common mechanism for ciliary central pair agenesis due to radial spoke defects. *Hum. Mol. Genet.* 2014; 23: 3362–3374.

96. Jeanson L, Copin B, Papon J-F, Dastot-Le Moal F, Duquesnoy P, Montantin G, Cadranel J, Corvol H, Coste A, Désir J, Souayah A, Kott E, Collot N, Tissier S, Louis B, Tamalet A, de Blic J, Clement A, Escudier E, Amselem S, Legendre M. RSPH3 Mutations Cause Primary Ciliary Dyskinesia with Central-Complex Defects and a Near Absence of Radial Spokes. *Am. J. Hum. Genet.* 2015; 97: 153–162.

97. Wirschell M, Olbrich H, Werner C, Tritschler D, Bower R, Sale WS, Loges NT, Pennekamp P, Lindberg S, Stenram U, Carlén B, Horak E, Köhler G, Nürnberg P, Nürnberg G, Porter ME, Omran H. The nexin-dynein regulatory complex subunit DRC1 is essential for motile cilia function in algae and humans. *Nat. Genet.* 2013; 45: 262–268.

98. Horani A, Brody SL, Ferkol TW, Shoseyov D, Wasserman MG, Ta-shma A, Wilson KS, Bayly P V, Amirav I, Cohen-Cymberknoh M, Dutcher SK, Elpeleg O, Kerem E. CCDC65 mutation causes primary ciliary dyskinesia with normal ultrastructure and hyperkinetic cilia. *PLoS One* 2013; 8: e72299.

99. Merveille A-C, Davis EE, Becker-Heck A, Legendre M, Amirav I, Bataille G, Belmont J, Beydon N, Billen F, Clément A, Clercx C, Coste A, Crosbie R, de Blic J, Deleuze S, Duquesnoy P, Escalier D, Escudier E, Fliegauf M, Horvath J, Hill K, Jorissen M, Just J, Kispert A, Lathrop M, Loges NT, Marthin JK, Momozawa Y, Montantin G, Nielsen KG, et al. CCDC39 is required for assembly of inner dynein arms and the dynein regulatory complex and for normal ciliary motility in humans and dogs. *Nat. Genet.* 2011; 43: 72–78.

100. Antony D, Becker-Heck A, Zariwala MA, Schmidts M, Onoufriadis A, Forouhan M, Wilson R, Taylor-Cox T, Dewar A, Jackson C, Goggin P, Loges NT, Olbrich H, Jaspers M, Jorissen M, Leigh MW, Wolf WE, Daniels MLA, Noone PG, Ferkol TW, Sagel SD, Rosenfeld M, Rutman A, Dixit A, O’Callaghan C, Lucas JS, Hogg C, Scambler PJ, Emes RD, Chung EMK, et al. Mutations in CCDC39 and CCDC40 are the major cause of primary ciliary dyskinesia with axonemal disorganization and absent inner dynein arms. *Hum. Mutat.* 2013; 34: 462–472.

101. Becker-Heck A, Zohn IE, Okabe N, Pollock A, Lenhart KB, Sullivan-Brown J, McSheene J, Loges NT, Olbrich H, Haeffner K, Fliegauf M, Horvath J, Reinhardt R, Nielsen KG, Marthin JK, Baktai G, Anderson K V, Geisler R, Niswander L, Omran H, Burdine RD. The coiled-coil domain containing protein CCDC40 is essential for motile cilia function and left-right axis formation. *Nat. Genet.* 2011; 43: 79–84.

102. Moore A, Escudier E, Roger G, Tamalet A, Pelosse B, Marlin S, Clément A, Geremek M, Delaisi B, Bridoux A-M, Coste A, Witt M, Duriez B, Amselem S. RPGR is mutated in patients with a complex X linked phenotype combining primary ciliary dyskinesia and retinitis pigmentosa. *J. Med. Genet.* 2006; 43: 326–333.

103. Zietkiewicz E, Loges NT, Wittmer M, Geremek M, Olbrich H, Fliegauf M, Voelkel K, Rutkiewicz E, Rutland J, Morgan L, Pogorzelski A, Martin J, Haan E, Berger W, Omran H, Witt M. RPGR mutations might cause reduced orientation of respiratory cilia. *Pediatr. Pulmonol.* 2013; 48: 352–363.

104. Budny B, Chen W, Omran H, Fliegauf M, Tzschach A, Wisniewska M, Jensen LR, Raynaud M, Shoichet SA, Badura M, Lenzner S, Latos-Bielenska A, Ropers H-H. A novel X-linked recessive mental retardation syndrome comprising macrocephaly and ciliary dysfunction is allelic to oral-facial-digital type I syndrome. *Hum. Genet.* 2006; 120: 171–178.

105. Boon M, Wallmeier J, Ma L, Loges NT, Jaspers M, Olbrich H, Dougherty GW, Raidt J, Werner C, Amirav I, Hevroni A, Abitbul R, Avital A, Soferman R, Wessels M, O’Callaghan C, Chung EMK, Rutman A, Hirst R a, Moya E, Mitchison HM, Van Daele S, De Boeck K, Jorissen M, Kintner C, Cuppens H, Omran H. MCIDAS mutations result in a mucociliary clearance disorder with reduced generation of multiple motile cilia. *Nat. Commun.* 2014; 5: 4418.

106. Zariwala MA, Leigh MW, Ceppa F, Kennedy MP, Noone PG, Carson JL, Hazucha MJ, Lori A, Horvath J, Olbrich H, Loges NT, Bridoux A-M, Pennarun G, Duriez B, Escudier E, Mitchison HM, Chodhari R, Chung EMK, Morgan LC, de Iongh RU, Rutland J, Pradal U, Omran H, Amselem S, Knowles MR. Mutations of DNAI1 in primary ciliary dyskinesia: evidence of founder effect in a common mutation. *Am. J. Respir. Crit. Care Med.* 2006; 174: 858–866.

107. Amirav I, Wallmeier J, Loges NT, Menchen T, Pennekamp P, Mussaffi H, Abitbul R, Avital A, Bentur L, Dougherty GW, Nael E, Lavie M, Olbrich H, Werner C, Kintner C, Omran H. Systematic Analysis of CCNO Variants in a Defined Population: Implications for Clinical Phenotype and Differential Diagnosis. *Hum. Mutat.* 2016; 37: 396–405.

108. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* 2015; 17: 405–424.

109. Lucas JS, Adam EC, Goggin PM, Jackson CL, Powles-Glover N, Patel SH, Humphreys J, Fray MD, Falconnet E, Blouin J-L, Cheeseman MT, Bartoloni L, Norris DP, Lackie PM. Static respiratory cilia associated with mutations in Dnahc11/DNAH11: a mouse model of PCD. *Hum. Mutat.* 2012; 33: 495–503.

110. Davis SD, Ferkol TW, Rosenfeld M, Lee H-S, Dell SD, Sagel SD, Milla C, Zariwala MA, Pittman JE, Shapiro AJ, Carson JL, Krischer JP, Hazucha MJ, Cooper ML, Knowles MR, Leigh MW. Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. *Am. J. Respir. Crit. Care Med.* American Thoracic Society; 2015; 191: 316–324.

111. Marshall CR, Scherer SW, Zariwala MA, Lau L, Paton TA, Stockley T, Jobling RK, Ray PN, Knowles MR, Hall DA, Dell SD, Kim RH. Whole-Exome Sequencing and Targeted Copy Number Analysis in Primary Ciliary Dyskinesia. *G3 (Bethesda).* 2015; 5: 1775–1781.

112. Djakow J, Svobodová T, Hrach K, Uhlík J, Cinek O, Pohunek P. Effectiveness of sequencing selected exons of DNAH5 and DNAI1 in diagnosis of primary ciliary dyskinesia. *Pediatr. Pulmonol.* 2012; 47: 864–875.

113. Failly M, Bartoloni L, Letourneau A, Munoz A, Falconnet E, Rossier C, de Santi MM, Santamaria F, Sacco O, DeLozier-Blanchet CD, Lazor R, Blouin J-L. Mutations in DNAH5 account for only 15% of a non-preselected cohort of patients with primary ciliary dyskinesia. *J. Med. Genet.* 2009; 46: 281–286.

114. Blanchon S, Legendre M, Copin B, Duquesnoy P, Montantin G, Kott E, Dastot F, Jeanson L, Cachanado M, Rousseau A, Papon JF, Beydon N, Brouard J, Crestani B, Deschildre A, Désir J, Dollfus H, Leheup B, Tamalet A, Thumerelle C, Vojtek A-M, Escalier D, Coste A, de Blic J, Clément A, Escudier E, Amselem S. Delineation of CCDC39/CCDC40 mutation spectrum and associated phenotypes in primary ciliary dyskinesia. *J. Med. Genet.* 2012; 49: 410–416.

115. Claustres M, Kožich V, Dequeker E, Fowler B, Hehir-Kwa JY, Miller K, Oosterwijk C, Peterlin B, van Ravenswaaij-Arts C, Zimmermann U, Zuffardi O, Hastings RJ, Barton DE. Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic). *Eur. J. Hum. Genet.* 2014; 22: 160–170.

116. Matthijs G, Souche E, Alders M, Corveleyn A, Eck S, Feenstra I, Race V, Sistermans E, Sturm M, Weiss M, Yntema H, Bakker E, Scheffer H, Bauer P. Guidelines for diagnostic next-generation sequencing. *Eur. J. Hum. Genet.* 2016; 24: 2–5.

117. Omran H, Loges NT. Immunofluorescence staining of ciliated respiratory epithelial cells. *Methods Cell Biol.* 2009; 91: 123–133.

118. Werner C, Lablans M, Ataian M, Raidt J, Wallmeier J, Große-Onnebrink J, Kuehni CE, Haarman EG, Leigh MW, Quittner AL, Lucas JS, Hogg C, Witt M, Priftis KN, Yiallouros P, Nielsen KG, Santamaria F, Ückert F, Omran H. An international registry for primary ciliary dyskinesia. *Eur. Respir. J.* 2016; 47: 849–859.

119. Rutjes AWS, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PMM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. *Health Technol. Assess.* 2007; 11: iii, ix – 51.

**Figure Legends**

**Figure 1:**  Diagram of normal ultrastructure of the ciliary axoneme in transverse section

**Figure 2:** Electron microscopy images of PCD defects. A. Inner and outer dynein arm defect, B. Outer dynein arm defect, C. Inner dynein arm and microtubular disarrangement, D. central pair and transposition defect

**Figure 3.**  Immunofluorescence microscopy can be used to identify structural defects of motile cilia and to aid diagnosis of PCD. Antibodies directed against the outer dynein arm heavy chain DNAH5 (red, A) can be used to detect outer dynein arm defects caused by various genetic defects. Antibodies against DNAH11 (green, B) can detect *DNAH11* loss-of function mutations that cause PCD with normal ultrastructure. The antibodies directed against GAS8 (red, C) can identify isolated defects of the nexin-dynein regulatory complex (C). Antibodies against CCDC39 (red, D) are used to detect defects of the 96nm axonemal ruler (D) caused by CCDC39 or CCDC40 mutations. Anti- RSPH9 antibodies (red, E) can be used to identify various defects of the radial spoke head complex (E). Normal localisation of ciliary components is shown by co-localisation (yellow color) with ciliary axonemal markers such as acetylated tubulin (green in A,D,E), alpha/beta tubulin (red in B) or unaffected ciliary components (i.e. DNAH5, green in C). In contrast, absence of structural components involved in ciliary motility is shown by absence of the protein in mutant cells (lower panels in A-E). Nuclei are shown in blue. Scale bars represent 10µm.

**Figure 4.** Following development of recommendations using the GRADE approach, a Delphi survey allowed us to propose a diagnostic algorithm for PCD. Not all patients need to go through all steps. Please see the text for details of the implications of each diagnostic outcome (positive, highly likely and highly unlikely), as well as the consequences for the many patients who will continue to have an inconclusive outcome using currently available diagnostic tests. Patients with uncertain outcomes should be reconsidered for further testing as advances in diagnostic tests are made.